*REVIEW ARTICLE*

# Pharmaceutical and Therapeutic Potentials of Essential Oils and Their Individual Volatile Constituents: A Review

**Amr E. Edris***

Aroma and Flavor Chemistry Department, National Research Center, Dokki, El Behose Street, Dokki, 12622, Cairo, Egypt

**Essential oils and their volatile constituents are used widely to prevent and treat human disease. The possible role and mode of action of these natural products is discussed with regard to the prevention and treatment of cancer, cardiovascular diseases including atherosclerosis and thrombosis, as well as their bioactivity as antibacterial, antiviral, antioxidants and antidiabetic agents. Their application as natural skin penetration enhancers for transdermal drug delivery and the therapeutic properties of essential oils in aroma and massage therapy will also be outlined. Copyright © 2007 John Wiley & Sons, Ltd.**

*Keywords:* essential oils; cancer; cardiovascular disease; antimicrobial; antidiabetic; penetration enhancer; aromatherapy; massage therapy.

## INTRODUCTION

Aromatic plants had been used since ancient times for their preservative and medicinal properties, and to impart aroma and flavor to food. Hippocrates, sometimes referred to as the 'father of medicine', prescribed perfume fumigations.

The pharmaceutical properties of aromatic plants are partially attributed to essential oils. The term 'essential oil' was used for the first time in the 16th century by Paracelsus von Hohenheim, who named the effective component of a drug, 'Quinta essential' (Guenther, 1950). By the middle of the 20th century, the role of essential oils had been reduced almost entirely to use in perfumes, cosmetics and food flavorings, while their use in pharmaceutical preparations had declined.

Essential oils are natural, complex, multi-component systems composed mainly of terpenes in addition to some other non-terpene components. Several techniques can be used to extract essential oils from different parts of the aromatic plant, including water or steam distillation, solvent extraction, expression under pressure, supercritical fluid and subcritical water extractions.

## ESSENTIAL OILS AND CANCER

Most cancer chemotherapy regimens make use of highly cytotoxic drugs that target proliferating cell populations. The non-discriminatory nature of these drugs leads to severe side effects in normal cells with a high prolifera-

tive index, such as those of the gastrointestinal tract and bone marrow, thus limiting the effective dose of anticancer drug that can be administered. The diverse therapeutic potential of essential oils has drawn the attention of researchers to test them for anticancer activity, taking advantage of the fact that their mechanism of action is dissimilar to that of the classic cytotoxic chemotherapeutic agents (Rajesh *et al.*, 2003). Early reports had indicated that essential oil components, especially monoterpenes, have multiple pharmacological effects on mevalonate metabolism which could account for the terpene-tumor suppressive activity (Elson, 1995).

Monoterpenes have been shown to exert chemopreventive as well as chemotherapeutic activities in mammary tumor models and thus may represent a new class of therapeutic agents. The mechanism of action of monoterpenes is based on two main approaches, chemoprevention and chemotherapy. Chemoprevention occurs during the initiation phase of carcinogenesis to prevent the interaction of chemical carcinogens with DNA, by induction of phase I and phase II enzymes to detoxify the carcinogen (Wattenberg, 1992). Chemotherapy works during the promotion phase, in which inhibition of tumor cell proliferation, acceleration of the rate of tumor cell death and/or induction of tumor cell differentiation may occur (Morse and Stoner, 1993).

### Chemoprevention

It is generally accepted that components that induce Phase I or II drug metabolizing enzymes can protect against chemical carcinogenesis or damage, especially during the initiation phase. Essential oils could be utilized to protect body organs against carcinogenesis; for instance, nutmeg, (*Myristica fragrans*), showed a potent hepatoprotective activity against liver damage

* Correspondence to: Amr E. Edris, Aroma and Flavor Chemistry Department, National Research Center, Dokki, El Behose Street, Dokki, 12622, Cairo, Egypt.
E-mail: amr_edris@hotmail.com

caused by certain chemicals (Morita *et al.*, 2003). The protective activity was correlated with myristicin, a major constituent. The mechanism of hepatoprotective activity of myristicin includes inhibition of TNF-$\alpha$ release from macrophages and suppression of apoptosis. Myristicin can also induce glutathione-S-transferase, a phase II detoxifying enzyme (Ahmad *et al.*, 1997), in addition to its activity of inhibiting benzo[a]pyrene-induced tumorigenesis in mouse tissues (Zheng *et al.*, 1992). Recently it was found that myristicin induces cytotoxicity in human neuroblastoma SK-N-SH cells by an apoptotic mechanism (Lee *et al.*, 2005).

Citral, which is found in many essential oils and comprises 70%–85% of lemongrass oil, is a novel monoterpene inducer of glutathione-S-transferase class $\pi$, (GSTP$_1$). This isozyme is responsible for the increase in the total GST activity of the citral-treated rat hepatocyte cells (Nakamura *et al.*, 2003). Structure–activity relationship studies revealed that *trans*-citral (geranial) was the main contributor for the induction of GSTP$_1$. The aldehyde group conjugated with a *trans*-double bond in *trans*-citral is an essential structural factor for GST induction. On the other hand *cis*-citral (neral) showed no activity. This suggested the exploration of citral as a cancer chemopreventive agent targeted towards inflammation-related carcinogenesis such as skin cancer (Henderson *et al.*, 1998) and colon cancer (Mulder *et al.*, 1995), both of which were found to be due to lack of GSTP$_1$ activity. The high content of citral in lemongrass oil may explain the inhibitory effect of that aromatic plant on the early phase of hepatocarcinogenesis in rats (Puatanachokchai *et al.*, 2002). Citral also increased the hepatic glutathione-S-transferase (GST) and aminopyrine demethylase activities, and reduced glucuronyl transferase activity (Vinitketkumnuen and Lertprasertsuk, 1997).

Although citral is generally recognized as safe for human consumption as a food additive by the FDA (GRAS), it is classified as a potential teratogen and primary irritant (Abramovici and Rachmuth-Roizman, 1983). The National Toxicology Program (2003) concluded that under the conditions of two-year feeding studies there was no evidence of carcinogenic activity of citral in male or female F344/N rats exposed to 1000, 2000 or 4000 ppm. There was no evidence of carcinogenic activity of citral in male B6C3F1 mice exposed to 500, 1000 or 2000 ppm. There was, however, equivocal evidence of carcinogenic activity in female B6C3F1 mice based on the increased incidence of malignant lymphoma, thus the acceptable daily intake (ADI) of citral has been proposed as 0–0.5 mg/kg/day (FAO/WHO 2003).

Other essential oils elicit hepatoprotective activity due to their phenolic and/or monoterpene content: for example, black cumin (*Nigella sativa*), due to thymoquinone (Mansour *et al.*, 2001); orange essential oil, due to *d*-limonene (Bodake *et al.*, 2002); and sweet fennel (*Foeniculum vulgare*) due to both *d*-limonene and $\beta$-myrcene (Ozbek *et al.*, 2003). In addition, *d*-limonene exhibits chemopreventive efficacy in preclinical hepatocellular carcinoma models (Parija and Das, 2003; Guyton and Kensler, 2002; Jiri *et al.*, 1999). The mode of action originates, in part, from the induction of the specific cytochrome P450 isozymes including CYP 2B1 and CYP2C (Maltzman *et al.*, 1991). *d*-Limonene is also a candidate for the chemoprevention

of skin cancer (Stratton *et al.*, 2000), although it can cause contact dermatitis, especially when oxidized.

Garlic essential oil is a rich source of volatile organosulfur components (OSCs). These compounds are recognized as a group of potential cancer chemopreventive agents due to their activity for modulating phase I and II drug detoxifying enzymes (Milner, 2001). The three major OSCs of garlic essential oil, diallyl sulfide (DAS), diallyl disulfide (DADS) and diallyl trisulfide (DATS), were found differentially to mediate the transcriptional levels of phase II detoxifying enzymes, NQO1 and HO1, in human hepatoma (HepG2) cells (Chen *et al.*, 2004). DATS, with three sulfur atoms, was found to be the most potent inducer of phase II enzyme gene expression, ARE activation and Nrf2 protein accumulation. The effects of oral administration of garlic essential oil and its three major OSCs on different phase I and phase II hepatic detoxification enzymes in rat showed that the essential oil and DAS significantly increased the activity of the phase I enzyme (PROD) (Wu *et al.*, 2002). DADS and DATS significantly decreased the activity of phase I enzyme (NDMAD). Garlic essential oil, DADS, and DATS significantly increased the activity of glutathione S-transferase, a phase II detoxifying enzyme. The placental form of GST (GST$\pi$) level was also increased by garlic oil and its three major components. GST$\pi$ is one of the GST isozymes which are of special interest due to their relationship with the development of human ovarian cancer (Hamada *et al.*, 1994) and colorectal cancer (Mulder *et al.*, 1995). The highest concentrations of DAS, DADS and DATS, which are decomposition products of allicin, are found in garlic essential oil extracted from crushed cloves using steam or water distillation (Ibrel *et al.*, 1990).

## Cancer suppression

Essential oils and their individual aroma components showed cancer suppressive activity when tested on a number of human cancer cell lines including glioma, colon cancer, gastric cancer, human liver tumor, pulmonary tumors, breast cancer, leukemia and others. Glioma is one of the most malignant human tumors (De Angelis, 2001).

$\alpha$–Bisabolol, a major sesquiterpene alcohol in Chamomile, (*Matricaria chamomilla*) essential oil, could be considered as a promising inducer of apoptosis in highly malignant glioma cells. It is neither toxic in animals nor does it reduce the viability of normal astroglial cells (Cavalieri *et al.*, 2004). A significant effect on the treatment of glioma was reported using the sesquiterpene hydrocarbon elemene which is found in small amounts in many essential oils: it prolonged quality survival time of patients with glioma (Tan *et al.*, 2000).

Geraniol, a monoterpene alcohol, elicited a dramatic reduction in the amounts of thymidylate synthase (TS) and thymidine kinase (TK) expression in colon cancer cells (Carnesecchia *et al.*, 2004). These two enzymes are involved in 5-fluorouracil (5-FU) toxicity, in that a decrease in these enzymes is related to enhanced 5-FU cytotoxicity (Mans *et al.*, 1999). Geraniol lowered the resistance of cancer cells to 5-FU thus potentiating the inhibition of tumor growth by the drug, and increasing the survival time of nude mice grafted with the human colorectal tumor cells TC118. Geraniol acts on at least

two different targets involved in the resistance of cancer cells to 5-FU: it increases cell membrane permeability leading to enhanced uptake of 5-FU by colon cancer cells and causes a significant change in the resting potential and cell membrane polarization, which may trigger modifications of membrane bound protein activity and alterations in intracellular signaling pathways (Carnesecchi *et al.*, 2002a, 2002b). A major natural source of geraniol is Palmarosa oil (*Cymbopogon martini* var *martini*), also known as East Indian geranium, containing 59%–84% which is much greater than most species of *Geranium* or *Pelargonium* (Sirinivas, 1986).

*d*-Limonene showed antiangiogenic and proapoptotic effects on human gastric cancer implanted in nude mice, thus inhibiting tumor growth and metastasis (Guang *et al.*, 2004). *d*-Limonene can also induce the formation of apoptotic bodies on BGC-823 gastric cancer cells in a dose- and time-dependent manner (Guang *et al.*, 2003) and its efficacy was increased by combining it with cytotoxic agents such as 5-fluorouracil. Administration of chow pellets containing 1% or 2% *d*-limonene to male Sprague-Dawley rats resulted in significant reductions in chemically induced, hepatocellular carcinomas (Kaji *et al.*, 2001). This effect could be related to its effect in inhibiting cell proliferation and in enhancing apoptosis. *d*-Limonene also increased the survival of lymphoma-bearing mice and modulated the immune response, showing significant potential for clinical application (Del Toro-Arreola *et al.*, 2005). A mechanism that may contribute to *d*-limonene efficacy in the chemoprevention and/or therapy of chemically induced human solid tumor cells has been proposed (Chen *et al.*, 1999; Jiri *et al.*, 1999; Parija and Das, 2003). Briefly, *d*-limonene can, in part, inhibit FPTase activity, inhibit the plasma-membrane associated P21ras expression, and the post-translational isoprenylation of P21ras. *d*-Limonene is found naturally in many essential oils, especially citrus fruit peel where it constitutes 90%–95% of the total oil. It is also found in considerable amounts (26%–34%) in some spearmint essential oils (Edris *et al.*, 2003). The annual production of *d*-limonene was estimated to be 50 000 tonnes (Braddock and Cadwallader, 1995) which makes its price as low as $1–2/kg (Mazzaro, 2000).

Diallyl trisulfide (DATS), a major constituent of garlic essential oil, showed a high activity for arresting the division of human liver tumor cells (J5) at the G2/M phase of the cell cycle (Wu *et al.*, 2004). The mechanism of action probably involves regulating the protein expressions of cyclin B1 and Cdk7. The chemotherapeutic and chemopreventive activity of garlic essential oil and its various organo-sulfur constituents against different types of carcinogenesis have been reviewed elsewhere (Thomson and Ali, 2003; Benjamin *et al.*, 1990).

It is accepted that aberrant angiogenesis is essential for the progression of solid tumors and hematological malignancies. Thus, antiangiogenic therapy is one of the most promising approaches to control cancer. Perillyl alcohol (POH) which is the hydroxylated analogue of *d*-limonene, has the ability to interfere with angiogenesis (Loutrari *et al.*, 2004). POH either alone or with PA (perillic acid, the major metabolite of POH in the body), has a potential use as an anticancer drug that stimulates different types of tumors to apoptosis, inhibits their proliferation, or overcomes their resistance to chemo-/radiotherapy (Yuri *et al.*, 2004; Samaila *et al.*, 2004; Elegbede *et al.*, 2003; Clark *et al.*, 2003; Rajesh *et al.*, 2003; Rajesh and Howard 2003; Ahn *et al.*, 2003; Bardon *et al.*, 2002; Burke *et al.*, 2002; Bardon *et al.*, 1998). The antitumor activity of POH emanates from its activity of modulating cellular processes that control cell growth and differentiation (Azzoli *et al.*, 2003; Clark *et al.*, 2002; Ariazi *et al.*, 1999; Ren and Gould, 1998; Gould, 1997 and Gould, 1995). Thus POH, among other micronutrients, was investigated by the National Cancer Institute (NCI) in NCI-sponsored phase I, II, or III chemoprevention trials for prostate, breast and colon cancers (Greenwald *et al.*, 2002). However, it may not be an effective chemopreventive agent for esophageal cancer in humans (Liston *et al.*, 2003). Unfortunately, despite evidence of anticancer activity of POH *in vitro*, oral administration has not yet shown any clinical antitumor activity (Bailey *et al.*, 2004; Azzoli *et al.*, 2003; Liu *et al.*, 2003; Meadows *et al.*, 2002; Howard *et al.*, 2002). POH is found in small amounts in many aromatic plants including lavender, peppermint, spearmint, perilla and lemongrass (Kelloff *et al.*, 1996). *Conyza newii* oil, (Compositae), contains 4.2% of perillyl alcohol (Omolo *et al.*, 2004) while *Tetradenia riparia* oil, (Labiateae) contains 6.0% POH (Campbell *et al.*, 1997). POH can also be produced from *d*-limonene by microbial biotransformation pathways (Duetz *et al.*, 2003).

Eucalyptol (1,8-cineol) is found in high concentrations (60%–90%) in the essential oil of eucalyptus (*Eucalyptus globulus*) (Juergens *et al.*, 1998) and 59% in cardamom (*Elettaria cardamomum*, Zingbraceae) (Huang *et al.*, 1999). Treatment of human leukemia HL-60 cells with eucalyptol showed morphological changes, (fragmentations of DNA) indicating an induction of apoptosis (Moteki *et al.*, 2002). However, this effect was not shown in human stomach cancer KATO III cells that received the same treatment with eucalyptol.

In addition to the individual terpene components mentioned above, several whole essential oils have also shown anticancer activity *in vitro*. The essential oil of lemon balm (*Melissa officinalis* L) was found to be effective against a series of human cancer cell lines (A549, MCF-7, Caco-2, HL-60, K562) and a mouse cell line (B16F10) (De Sousa *et al.*, 2004) and that of *Artemisia annua* L. induced apoptosis of cultured SMMC-7721 hepatocarcinoma cells (Li *et al.*, 2004). The essential oil of Australian tea tree (*Melaleuca alternifolia*) and its major monoterpene alcohol, terpinen-4-ol, were able to induce caspase-dependent apoptosis in human melanoma M14 WT cells and their drug-resistant counterparts, M14 adriamicin-resistant (Calcabrini *et al.*, 2004). There was evidence to suggest that the effect of the total oil and of terpinen-4-ol was mediated by their interaction with the plasma membrane and subsequent reorganization of membrane lipids.

Hepatic arterial infusion with *Curcuma* oil had a similar positive effect in treating primary liver cancer as that of the chemical drugs (Cheng *et al.*, 2001). The essential oil of *Tetraclinis articulate*, (a conifer tree) showed the hallmarks of apoptosis when tested on a number of human cancer cell lines including melanoma, breast and ovarian cancer in addition to peripheral blood lymphocytes (Buhagiar *et al.*, 1999).

These results may draw the attention of cancer researchers to further extend their clinical testing of essential oils, and it would be interesting to investigate the antitumor activity of a major individual terpene constituent in comparison with its whole essential oil source.

## ESSENTIAL OILS AND CARDIOVASCULAR DISEASES

### Atherosclerosis

Atherosclerosis is a process in which deposits of plaque build up in the innermost layer of the artery, the intima (Barter, 2005). Plaque can eventually significantly reduce blood flow, leading to serious health problems. Increased concentrations of oxidatively modified low density lipoproteins (LDLs) in cholesterol play a substantial role in disease initiation (Barter, 2005; Valenzuela *et al.*, 2004; Steinberg, 1997, Daugherty and Roselaar, 1995). Atherosclerosis can therefore be slowed down or inhibited by preventing the oxidation of LDLs using a high daily intake of antioxidants.

Essential oils and their aroma volatile constituents have shown an antioxidative activity against LDL oxidation. Terpinolene, a monoterpene hydrocarbon, can effectively inhibit the oxidation of both the lipid part and the protein part of LDL. This inhibition is due to a retarded oxidation of intrinsic carotenoids of LDL, and not, as is the case with some flavonoids, to the protection of intrinsic $\alpha$-tocopherol (Grassmann *et al.*, 2003, 2005). Essential oils rich in phenolic constituents such as eugenol and thymol have the highest antioxidative activity against LDL oxidation (Naderi *et al.*, 2004) and these components can also change the affinity of the LDL particles for the LDL receptor. A relationship was found between the quantity and quality of phenolic components in the oil and its protection against LDL oxidation: for instance, copper-catalysed oxidation of human LDL *in vitro* is inhibited by 50%–100% when eugenol is the major component of the essential oil (as in clove oil), while inhibition was only 10%–50% for essential oils containing moderate amounts of the phenolics, thymol, carvacrol or cuminol (Teissedre and Waterhouse, 2000). In addition to the phenolic constituents, the monoterpene hydrocarbon $\gamma$-terpinene, was also found to inhibit LDL oxidation, even in the propagation phase. $\gamma$-Terpinene generated an antioxidative effect on the $Cu^{2+}$-induced and AAPH-induced oxidation of human LDL *in vitro* (Takahashi *et al.*, 2003). Tea tree essential oil is considered to be a rich source of $\gamma$-terpinene (23.0%) (Brophy *et al.*, 1989) and $\gamma$-terpinene is also found in considerable amounts in some citrus peel essential oils such as bergamot (14%), mandarin (17%) and lemon (10%) (Mondello *et al.*, 1995). It has been recommended as an addition to foods and beverages to protect against LDL oxidation and to reduce plaque formation (Takahashi *et al.*, 2003).

Essential oils and some of their individual constituents can also lower total plasma cholesterol and triglyceride levels which contribute to the formation of plaque and consequently, atherosclerosis. Black cumin oil (*Nigella sativa* Linn.) was found to decrease plasma concentrations of cholesterol and triglycerides due to the high content of thymoquinone (Ali and Blunden, 2003). The essential oil of *Satureja khuzestanica*, an endemic plant of Iran, was reported to decrease the normal blood lipid peroxidation level (Abdollahi *et al.*, 2003). Oral administration of dill seed essential oil (*Anethum graveolens*) reduced triacylglyceride levels by almost 42%, although total cholesterol level was not reduced (Yazdanparast and Alavi, 2001). $\alpha$-Curcumene, the major constituent (approx. 65%) of the essential oil of Javanese turmeric (*Curcuma xanthorrhiza*), exerts triglyceride-lowering activity on serum as well as liver triglycerides (Yasni *et al.*, 1994).

Garlic essential oil significantly lowered serum cholesterol and triglycerides while raising the level of high-density lipoproteins in both healthy individuals and patients with coronary heart disease (Bordia, 1981). The hypolipidemic action of garlic oil is primarily due to a decrease in hepatic cholesterogenesis (Mathew *et al.*, 1996). One of the consequences of atherosclerosis is hypertension, and some essential oils exert hypotensive activity when applied *in vivo*. Oral administration of combinations of oregano, cinnamon, cumin, and other essential oils decreased systolic blood pressure in rats (Talpur *et al.*, 2005) and intravenous administration of the essential oil from the aerial parts of *Mentha x villosa* induced a significant and dose-dependent hypotension associated with decreases in heart rate (Guedes *et al.*, 2004). This activity was attributed to the volatile component, piperitenone oxide, which represents 55.4% of the oil. The hypotensive effect induced by the oil is probably due to its direct cardiodepressant action and peripheral vasodilation, which can be attributed to both endothelium-dependent and endothelium-independent mechanisms.

Intravenous administration of the essential oil of basil (*Ocimum gratissimum*) induced an immediate and significant hypotension and bradycardia (Lahlou *et al.*, 2004). The hypotensive activity of the essential oil resulted from its vasodilator effects, acting directly upon vascular smooth muscle. This effect was attributed, at least in part, to the actions of eugenol, which is the major constituent of the oil. Clove bud essential oil is the richest source of eugenol known (about 80%; Deyama and Horiguchi, 1971) but from a safety point of view, care must be taken in dealing with eugenol due to its suspected carcinogenicity and hepatotoxicity (National Toxicology Program, 1983).

Intravenous injection of the monoterpene alcohol terpinen-4-ol decreased mean aortic blood pressure in a dose-related manner, in conscious DOCA-salt hypertensive rats (Lahlou *et al.*, 2003). The mechanism of action was related to the induction of vascular smooth muscle relaxation rather than enhanced sympathetic nervous system activity. Terpinene-4-ol is a major constituent of several essential oils, particularly tea tree (Brophy *et al.*, 1989) and sweet marjoram essential oils (Nykanen, 1986).

### Essential oils and thrombosis

Thrombosis is usually associated with platelet activation and the release of eicosanoids which contribute to initiation and aggravation of thrombosis. Prevention of

thrombogenesis has become one of the most important targets for the prophylaxis and therapy of cardiocirculatory disorders with thromboembolic complications (Fitzgerald, 2001). The antiplatelet agents currently used for this purpose are effective in the prevention of thromboembolic disease, but many have side effects such as gastric erosion (e.g. aspirin), agranulocytosis (e.g. ticlopidine), or show a poor separation between therapeutic efficacy and hemorrhagic complications (Van De Graaff and Steinhubl, 2001). For this reason, plant extracts have been tested for their potential antithrombotic activity. The essential oil of lavender, (*Lavandula hybrida* Reverchon cv.), showed a broad spectrum antiplatelet effect and was able to inhibit platelet aggregation induced by ADP, arachidonic acid, collagen and the stable thromboxane receptor agonist U46619 with no prohemorrhagic properties (Ballabenia *et al.*, 2004). Linalyl acetate (36% of lavender oil) seemed to be the main active antiplatelet agent. Onion (*Allium cepa*) is well known for promoting cardiovascular health, and populations with a high consumption of onions are associated with decreased rates of atherosclerosis or thrombotic disease (Kendler, 1987). This activity is due to inhibition of platelet aggregation and thromboxane formation by the organo-sulfur components in the essential oil (Bordia *et al.*, 1996; Srivastava, 1986). The mechanism of the antiplatelet effect of onion includes TXA2 synthase inhibition and TXA2/PGH2 receptor blockade (Moon *et al.*, 2000). However, garlic was found to be more potent than onion in lowering TXB2 levels (Bordia *et al.*, 1996). Organo-sulfur components such as allicin, isolated from garlic essential oil, showed a potent inhibition of platelet aggregation (Calvey *et al.*, 1994; Lawson *et al.*, 1992). Allicin is formed from alliin when garlic cloves are crushed or chewed and the enzyme alliinase is released from the cell walls. However, ajoene has the highest specific antithrombotic activity compared with any other organo-sulfur compounds from garlic (Lawson *et al.*, 1992; Apitz-Castro *et al.*, 1983). Ajoene is formed from allicin during steam or water distillation of the essential oil from garlic cloves, or during storage in ethanol (Block *et al.*, 1986, Iberl *et al.*, 1990). The presence of vinyl groups attached by a disulfide bond makes ajoene a highly reactive molecule which can inhibit the release of both dense granules and $\alpha$-granules (Rendu *et al.*, 1989). Ajoene can reduce platelet aggregation induced by 0.1 U/mL thrombin by 94.7% after a pre-stimulation incubation time for one minute at a dose of 25 μM (Villar *et al.*, 1997). The mechanism of action of ajoene differs to that of other known inhibitors of platelet aggregation. Ajoene penetrates the membrane of intact platelets and reduces the viscosity of the inner part of the lipid bilayer (Rendu *et al.*, 1989), thus interfering with the expression of the fibrinogen receptor $\alpha_{IIB}$ $\beta_3$ at the cell surface, thereby inhibiting fibrinogen binding (Apitz-Castro *et al.*, 1986). Ajoene also inhibits platelet aggregation through inhibiting the formation of thromboxane A2 via altering arachidonic acid metabolism. Moreover, it inhibits platelet aggregation induced by adrenaline, collagen, adenosine diphosphate and calcium ionophore A23187 (Srivastava and Tyagi, 1993). Polysulfides, particularly dimethyl trisulfide and diallyl trisulfide, found in both onion and garlic oils also inhibit thromboxane synthesis in platelets (Makheja and Bailey, 1990).

## ESSENTIAL OILS AS ANTIBACTERIAL AGENTS

The Ancient Egyptians used aromatic plants in embalming to stop bacterial growth and prevent decay, an effect attributed to a great extent to their essential oils. Strong *in vitro* evidence indicates that essential oils can act as antibacterial agents against a wide spectrum of pathogenic bacterial strains including *Listeria monocytogenes*, *L. innocua*, *Salmonella typhimurium*, *Escherichia coli* O157:H7, *Shigella dysenteria*, *Bacillus cereus*, *Staphylococcus aureus* and *Salmonella typhimurium* (Schmidt *et al.*, 2005; Jirovetz *et al.* 2005; Burt, 2004; Dadalioglu and Evrendilek, 2004; Nguefack *et al.*, 2004; Hulin *et al.*, 1998) and many more (Deans and Ritchie, 1987). Thyme and oregano essential oils can inhibit some pathogenic bacterial strains such as *E. coli*, *Salmonella enteritidis*, *Salmonella choleraesuis* and *Salmonella typhimurium* (Penalver *et al.*, 2005), with the inhibition directly correlated to the phenolic components carvacrol and thymol. The same correlation was also confirmed for oils rich in carvacrol alone (Santoyo *et al.*, 2006). Eugenol and carvacrol showed an inhibitory effect against the growth of four strains of *Escherichia coli* O157:H7 and *Listeria monocytogenes* (Gaysinsky *et al.*, 2005). The presence of a phenolic hydroxyl group, in carvacrol particularly, is credited with its activity against pathogens such as *Bacillus cereus* (Ultee *et al.*, 1999; Ultee *et al.*, 2002). Some essential oils demonstrated antibacterial activity against zoonotic enteropathogens including *Salmonella spp.*, *Escherichia coli O157*, *Campylobacter jejunii* and *Clostridium perfringens*. Thus, these oils could possibly be used as an alternative to antibiotics in animal feed (Wannissorn *et al.*, 2005).

Essential oils with high concentrations of thymol and carvacrol e.g. oregano, savory and thyme, usually inhibit Gram-positive more than Gram-negative pathogenic bacteria (Nevas *et al.*, 2004). However the essential oil of *Achillea clavennae* exhibited strong antibacterial activity against the Gram (−)-ve *Haemophilus influenzae* and *Pseudomonas aeruginosa* respiratory pathogens, while Gram (+)-ve *Streptococcus pyogenes* was the most resistant to the oil (Skocibusic *et al.*, 2004).

The major mode of infection transmission in hospital-acquired infections is thought to be through hand carrying of pathogens from staff to patient, and from patient to patient (Boyce and Pittet, 2002; Naikoba and Hayward, 2001), and a relationship between hand hygiene and reduced transmission of infections been reported (Reybrouck, 1986). Most antiseptic agents can damage the skin, leading to a change in microbial flora, and an increased shedding of the original protective bacterial flora of the hand leads to an increased risk of transmission of pathogenic microorganisms (Larson, 2001). Reports suggest that repeated use of formulations containing tea tree essential oil (TTO) does not lead to dermatological problems, nor affect the original protective bacterial flora of the skin (Carson and Riley, 1995), so the antibacterial activity of some skin-wash formulas containing TTO as well as pure TTO was evaluated against *Staphylococcus aureus*, *Acinetobacter baumannii*, *Escherichia coli* and *Pseudomonas aeruginosa* (Messager *et al.*, 2005a, 2005b). All formulations showed antibacterial activity, but the efficacy of

TTO appeared to be dependent on the formulation and the concentration tested. The antibacterial activity of tea tree essential oil has recently been reviewed (Carson *et al.*, 2006).

In the field of veterinary therapy, a cream formulation containing 10% TTO caused significant and fast relief against canine localized acute and chronic dermatitis compared with commercial skin care cream (Reichling *et al.*, 2004). For the safe use of tea tree essential oil as antibacterial agent for animals or humans, the potential toxicity should be taken into consideration (Carson *et al.*, 2006; Hammer *et al.*, 2005; Carson and Riley, 1995).

The emergence of resistant pathogenic microorganisms in hospitals and in the community represents a problem for both the treatment of patients and control of infection. Topical preparations containing TTO can be considered in regimens for eradication of methicillin-resistant *Staphylococcus aureus* in hospitals (Dryden *et al.*, 2004). The preparations were found to be effective, safe and well tolerated. TTO demonstrated a relatively short killing time (less than 60 min) for multidrug-resistant organisms, including methicillin-resistant *Staphylococcus aureus* (MRSA), glycopeptide-resistant *Enterococci*, aminoglycoside-resistant *Klebsiellae*, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia* (May *et al.*, 2000). MRSA showed the highest resistance and longest time for eradication. It was concluded that the antimicrobial activity of TTO is attributed to its high content of terpenen-4-ol.

Other multidrug-resistant pathogens such as *Pseudomonas aeruginosa* and *Escherichia coli* can be effectively inhibited by the essential oil of oregano (Bozin *et al.*, 2006).

*Ocimum gratissimum* essential oil can also inhibit extracellular protease and the expression of O-lipopolysaccharide rhamnose in virulence and multidrug-resistant strains of 22 *Shigellae* (Iwalokun *et al.*, 2003). Thus, the oil may find a use as a therapeutic measure against shigellosis. Methicillin-resistant *Staphylococcus aureus* can also be inhibited by the application of peppermint and spearmint essential oils (Imai *et al.*, 2001). Essential oils could be used as antibacterial agents against some respiratory tract pathogens. The oil of *Achillea clavennae* showed its maximum activity against *Klebsiella pneumoniae* and penicillin-susceptible and penicillin-resistant *Streptococcus pneumoniae*. The oil also exhibited strong activity against *Haemophilus influenzae* and *Pseudomonas aeruginosa* (Skocibusic *et al.*, 2004).

An increased density of *Helicobacter pylori* in the gastric mucosa is associated with severe gastritis and an increased incidence of peptic ulcers (Kelly, 1998). The activities of 60 essential oils against *H. pylori* P1 were evaluated: 30 oils were able to affect the growth *in vitro*, and 15 showed strong activity (Bergonzelli *et al.*, 2003). Among the individual constituents of these oils, carvacrol, isoeugenol, nerol, citral and sabinene exhibited the strongest anti-*H. pylori* effects. Further investigations are underway regarding the ability of essential oils to control *H. pylori* infections (McNulty *et al.*, 2001; Kalpoutzakis *et al.*, 2001; Imai *et al.*, 2001; O'Gara *et al.*, 2000).

Essential oils show bactericidal activity against oral and dental pathogenic microorganisms and can be incorporated into rinses or mouth washes for pre-procedural infection control (Yengopal, 2004a),

general improvement of oral health (Yengopal, 2004b), interdental hygiene (Yengopal, 2004c) and to control oral malodor (Yengopal, 2004d). *Croton cajucara* Benth essential oil was found to be toxic for some pathogenic bacteria and fungi associated with oral cavity disease (Alviano *et al.*, 2005) and may be useful for controlling the microbial population in patients with fixed orthodontic appliances. A 6-month controlled clinical study demonstrated that a mouthrinse containing essential oils showed a comparable antiplaque and antigingivitis activity to that containing the synthetic antibacterial agent, chlorhexidine (Charles *et al.*, 2004). Mouth rinses containing essential oils (specially phenolic rich types) with chlorhexidine gluconate are commonly used as preprocedural preparations to prevent possible disease transmission, decrease chances of postoperative infection, decrease oral bacterial load and decrease aerosolization of bacteria (Hennessy and Joyce, 2004). Mouth washes containing essential oils could also be used as a part of plaque-control routine since they can penetrate the plaque biofilm, kill pathogenic-plaque-forming microorganisms by disrupting their cell walls and inhibiting their enzymatic activity (Ouhayoun, 2003). In addition, essential oils in mouth washes prevent bacterial aggregation, slow the multiplication and extract bacterial endotoxins (Seymour, 2003).

The mechanisms by which essential oils can inhibit microorganisms involve different modes of action, and in part may be due to their hydrophobicity. As a result, they get partitioned into the lipid bilayer of the cell membrane, rendering it more permeable, leading to leakage of vital cell contents (Burt, 2004; Juven *et al.*, 1994; Kim *et al.*, 1995). Impairment of bacterial enzyme systems may also be a potential mechanism of action (Wendakoon and Sakaguchi, 1995).

## ESSENTIAL OILS AS ANTIVIRAL AGENTS

*Herpes simplex* virus (type I, II) causes some of the most common viral infections in humans, and can be fatal. Synthetic antiviral drugs have been used to treat Herpes infections (Fahad and Stepher, 1996; Wagstaff *et al.*, 1994), but not all are efficacious in treating genital herpes infections. HSV-1 and HSV-2 have also developed resistance to one of these (acyclovir) mainly in immuno-compromised hosts (Birch *et al.*, 1990; Wagstaff *et al.*, 1994). Plant extracts, especially essential oils, may afford a potential alternative to synthetic antiviral drugs: they have demonstrated virucidal properties, with the advantage of low toxicity compared with the synthetic antiviral drugs (Baqui *et al.*, 2001; Primo *et al.*, 2001; Schnitzer *et al.*, 2001). Incorporation of *Artemisia arborescens* essential oil in multilamellar liposomes greatly improved its activity against intracellular *Herpes simplex* virus type-1 (HSV-1) (Sinicoa *et al.*, 2005). *Melissa officinalis* L. essential oil can inhibit the replication of HSV-2, due to the presence of citral and citronellal (Allahverdiyev *et al.*, 2004) and the ability to replicate of HSV-1 can be suppressed by incubation with different essential oils *in vitro*. Of these, lemongrass essential oil possessed the most potent anti-HSV-1 activity and completely inhibited viral replication after incubation for 24 h, even at a concentration of 0.1% (Minami *et al.*, 2003). Peppermint

(*Mentha piperita*) essential oil exhibited high levels of virucidal activity against HSV-1, HSV-2 and acyclovir-resistant strain of HSV-1 in viral suspension tests (Schuhmacher *et al.*, 2003). The antiviral activity of the oil was confirmed when the virus was pretreated with the essential oil prior to adsorption. The essential oil of *Lippia junelliana* and *Lippia turbinate* showed a potent inhibition against Junin virus (Garcia *et al.*, 2003). Australian tea tree essential oil and to a lesser extent, eucalyptus essential oil, demonstrated antiviral activity against HSV-1,2 (Schnitzler *et al.*, 2001). Both oils affected the virus before or during adsorption, but not after penetration into the host cell. The essential oil of *Santolina insularis* showed an antiviral activity *in toto* against HSV-1 and HSV-2 *in vitro* and was capable of preventing cell-to-cell virus spread in infected cells (De Logu *et al.*, 2000). The oil directly inactivated virus particles, thus preventing adsorption of virion to host cells. Isoborneol, a common monoterpene alcohol, showed dual virucidal activity against HSV-1 (Armaka *et al.*, 1999) and specifically inhibited glycosylation of viral polypeptides. Unfortunately, no literature was found concerning the antiviral applications of essential oils against epidemic viruses such as HIV or hepatitis C viruses, but the promising results illustrated here may promote further investigations in this area.

## ESSENTIAL OILS AS ANTIOXIDANTS

Free radicals and other reactive oxygen species cause oxidation of biomolecules including proteins, amino acids, unsaturated lipids and DNA, and ultimately produce molecular alterations related to aging, arteriosclerosis and cancer (Gardner, 1997), Alzheimer's disease (Butterfield and Lauderback, 2002), Parkinson's disease, diabetes and asthma (Zarkovic, 2003). The human body is equipped with an inherent defense system which can quench free radicals present in almost all cells (Halliwell and Gutteridge, 1990). An imbalance between free radical production and their removal by the body's antioxidant system leads to a phenomena known as 'oxidative stress' (Abdollahi *et al.*, 2004; McCord, 2000). In this situation, an external supply of antioxidants is necessary to regain a balance between free radicals and antioxidants.

Essential oils, as natural sources of phenolic components, attract investigators to evaluate their activity as antioxidants or free radical scavengers. The essential oils of basil, cinnamon, clove, nutmeg, oregano and thyme have proven radical-scavenging and antioxidant properties in the DPPH radical assay at room temperature (Tomaino *et al.*, 2005). The order of effectiveness was found to be: clove >> cinnamon > nutmeg > basil ≥ oregano >> thyme. The essential oil of *Thymus serpyllus* showed a free radical scavenging activity close to that of the synthetic butylated hydroxytoluene (BHT) in a $\beta$-carotene/linoleic acid system (Tepe *et al.*, 2005). The antioxidant activity was attributed to the high content of the phenolics thymol and carvacrol (20.5% and 58.1%, respectively). *Thymus spathulifolius* essential oil also possessed an antioxidant activity due to the high thymol and carvacrol content (36.5%, 29.8%, respectively; Sokmen *et al.*, 2004). The antioxidant activity of oregano (*Origanum vulgare* L., ssp. *hirtum*) essential

oil was comparable to that of $\alpha$-tocopherol and BHT, but less effective than ascorbic acid (Kulisic *et al.*, 2004). The activity is again attributed to the content of thymol and carvacrol (35.0%, 32.0%, respectively). Although dietary supplementation of oregano oil to rabbits delayed lipid oxidation, this effect was less than that of supplementation with the same concentration of $\alpha$-tocopheryl acetate (Botsoglou *et al.*, 2004). However, when tested on turkeys it showed an equivalent performance to the same concentration of $\alpha$-tocopheryl acetate in delaying iron-induced, lipid oxidation (Papageorgiou *et al.*, 2003).

The essential oils of *Salvia cryptantha* and *Salvia multicaulis* have the capacity to scavenge free radicals. The activity of these oils was higher than that of curcumin, ascorbic acid or BHT (Tepe *et al.*, 2004). The essential oil of *Achillea millefolium* subsp. *millefolium* (Asteraceae) exhibited a hydroxyl radical scavenging effect in the $Fe^{3+}$–EDTA–$H_2O_2$ deoxyribose system and inhibited the non-enzymatic lipid peroxidation of rat liver homogenate (Candan *et al.*, 2003). In addition, *Curcuma zedoaria* essential oil was found to be an excellent scavenger for DPPH radical (Mau *et al.*, 2003).

The antioxidant activity of essential oils cannot be attributed only to the presence of phenolic constituents; monoterpene alcohols, ketones, aldehydes, hydrocarbons and ethers also contribute to the free radical scavenging activity of some essential oils. For instance, the essential oil of *Thymus caespititius*, *Thymus camphoratus* and *Thymus mastichina* showed antioxidant activity which in some cases was equal to that of $\alpha$-tocopherol (Miguel *et al.*, 2004). Surprisingly, the three species are characterized by high contents of linalool and 1,8-cineole, while thymol or carvacrol are almost absent. The essential oil of lemon balm (*Melissa officinalis* L.) shows an antioxidant and free radical scavenging activity (Mimica-Dukic *et al.*, 2004) with the most powerful scavenging constituents comprising neral/geranial, citronellal, isomenthone and menthone. Tea tree (*Melaleuca alternifolia*) oil has been suggested as a natural antioxidant alternative for BHT (Kim *et al.*, 2004) with the inherent antioxidant activity attributed mainly to the $\alpha$-terpinene, $\gamma$-terpinene and $\alpha$-terpinolene content. Essential oils isolated from *Mentha aquatica* L., *Mentha longifolia* L. and *Mentha piperita* L., were able to reduce DPPH radicals into the neutral DPPH-H form (Mimica-Dukic *et al.*, 2003). The most powerful scavenging constituents was found to be 1,8-cineole for the oil of *M. aquatica* while menthone and isomenthone were the active principles of *M. longifolia* and *M. piperita*.

It is clear that essential oils may be considered as potential natural antioxidants and could perhaps be formulated as a part of daily supplements or additives to prevent oxidative stress that contributes to many degenerative diseases.

## ESSENTIAL OILS AS ANTIDIABETIC AGENTS

Diabetes is a disease in which the body does not produce or properly use insulin.

Investigators have conducted few studies exploring the potential benefits of essential oils as hypoglycemic agents and publications on the subject are scarce. Some

essential oils may aggravate diabetes: for instance, rosemary essential oil showed hyperglycemic and insulin release inhibitory effects in diabetic rabbits (Al-Hader *et al.*, 1994). Broadhurst *et al.* (2000) have emphasized that the lipophilic fraction of aromatic plants (i.e. essential oils) are not generally responsible for any antidiabetic activity showed by these plants, but Talpur *et al.* (2005) indicated that an oral administration of a combination of essential oils including cinnamon, cumin, fennel, oregano, myrtle besides others, was able to enhance insulin sensitivity in type 2 diabetes, in addition to lowering circulating glucose in the tolerance testing in rats. The essential oil of *Satureja khuzestanica* resulted in significant decreases in fasting blood glucose level in diabetic rats (Abdollahi *et al.*, 2003). More research is needed to confirm the veracity of the hypoglycemic activity of other essential oils and to elucidate their mechanism of action.

## ESSENTIAL OILS AS SKIN PENETRATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY

The oral and nasal routes are the most common non-invasive paths for drug administration but are not suitable for some drugs, either due to stomach acidity or hepatic first-pass metabolism (Balfour and McTavish, 1992; Corson, 1993). Nasal delivery is often characterized by poor absorption of lipophilic drugs (Orive *et al.*, 2003). Thus, the skin can present a promising route for administration of drugs in a non-invasive way. This phenomena is called topical or transdermal drug delivery. The principle barrier to topical drug delivery is the stratum corneum (SC) which is the outer most layer of the skin. The permeability of the SC can be increased by using skin penetration enhancers (Barry, 1991). Detailed reviews describing synthetic enhancers are available (Williams and Barry, 2004; Ghafourian *et al.*, 2004).

Essential oils and their terpene constituents may be acceptable natural alternatives to synthetic skin penetration enhancers. They are characterized by their relatively low price and promising penetration enhancing activities. The mechanism of skin penetration enhancing activity of terpenes was postulated (Vaddi *et al.*, 2002; Higaki *et al.*, 2003; Cornwell and Barry, 1994; Barry, 1991; Cornwell and Barry, 1991; Williams and Barry, 1991; Williams and Barry, 1989). Due to the popularity of these essential oils, their toxicities are well documented (Opdyke, 1974–1976), and found to be relatively low compared with most synthetic penetration enhancers. The evaluation of the sensitization, carcinogenicity and toxicity of these oils and their individual terpene constituents are continuously carried out by organizations such as the Research Institute for Fragrance Materials (RIFM), International Flavor and Fragrance Association (IFRA), Flavor Essence Manufacturers Association (FEMA) and the National Toxicology Program (NTP).

Terpenes such as menthol and cineole were employed as natural enhancers to improve the skin penetration of propranolol, a *β*-blocker, which has a short biological half-life and is subjected to extensive hepatic first-pass metabolism (Amnuaikit *et al.*, 2005). Cineole and menthol are reported to improve the skin permeation of hydrophilic drugs better than other terpenes (Narishetty and Panchagnula, 2004). Menthol and limonene produced maximum permeation of melatonin along with traditional enhancers including fatty alcohols and fatty acids (Kanikkannan *et al.*, 2004). On the other hand, menthol and menthone failed to enhance the penetration of high-molecular-weight, lipophilic drugs such as paclitaxel (Panchagnula *et al.*, 2004). The combination of two penetration enhancers of different classes such as terpenes (e.g. cineole) and fatty acids (e.g. oleic acid), synergistically enhanced transdermal flux of zidovudine in addition to reducing lag time. On the other hand, combinations of menthol with oleic or linolenic acid did not enhance transdermal delivery (Thomas and Panchagnula, 2003). The proper choice of the terpene enhancer is dictated by the lipophilicity or hydrophicity of the drug (El-Kattan *et al.*, 2001).

Some essential oils themselves have been investigated as potential skin penetration enhancers. Basil essential oil showed an enhancing activity for accelerating transdermal delivery of indomethacin (Fang *et al.*, 2004). The mechanism of action is probably due to the increased skin–vehicle partitioning by the oils. Niaouli essential oil showed a high activity for the permeation of estradiol through hairless mouse skin *in vitro* (Monti *et al.*, 2002). In addition, eucalyptus and chenopodium essential oils caused a near 30-fold increase in the 5-fluorouracil permeability coefficient (Williams and Barry, 1989).

## ESSENTIAL OILS, AROMATHERAPY AND MASSAGE THERAPY

The word 'aromatherapy' combines two words: aroma (a fragrance or swee smell) and therapy (a treatment). Aroma and massage therapy are the practice of using essential oils for psychological and physical well-being via inhalation or massage.

The term 'aromatherapy' may be confusing to non-specialists because it is used to describe a wide range of practices involving odorous substances. Thus, massage therapy, even when using essential oils, cannot be considered as aromatherapy. Only aroma delivery through inhalation, to induce psychological or physical effects, can be defined as aromatherapy (Buchbauer and Jirovetz, 1993, 1994). Nevertheless, the clinical use of essential oils and their volatile constituents via inhalation or massage has expanded worldwide.

### Inhalation

Inhalation of essential oils or their individual volatile terpenes has a significant role in controlling the central nervous system. For instance, aroma inhalation of *Storax pill* essential oil and preinhalation of *Acorus gramineus* rhizome essential oil are used in Chinese folk medicine in the treatment of epilepsy (Koo *et al.*, 2004; Koo *et al.*, 2003). The oils showed an inhibitory effect on the central nervous system via the gamma-aminobutyric acid (GABA)-ergic neuromodulation system. This effect originates from the enhancement of GABA levels in the brain (Koo *et al.*, 2003). The fragrance compounds,

*cis*-jasmone and methyl jasmonate, which characterize the aroma of *Jasminum grandiflorum* have a tranquillizing effect on the brain upon inhalation (Hossain *et al.*, 2004). They significantly increased the sleeping time of mice induced by pentobarbital. This indicates that these fragrant compounds were absorbed by the brain and thereby potentiated the GABA receptor response. Cedrol, which is a major component of cedarwood essential oil, showed a sedative effect and prolonged pentobarbital-induced sleeping time in rats upon inhalation (Kagawa *et al.*, 2003). The vapor of lavender essential oil or one of its main components, linalool, may contribute to relieving tension when inhaled. They may also be applicable to the treatment of menopausal disorders via inhalation (Yamada *et al.*, 2005). Lavender (*Lavandula hybrida* Reverchon 'Grosso') essential oil demonstrated an interesting analgesic activity, mainly relevant after inhalation, at doses devoid of sedative side effects (Barocelli *et al.*, 2004). In the field of complementary and alternative respiratory medicine, inhalation of peppermint essential oil vapors has been suggested as an adjunct in combined multidrug therapy in patients with disseminated and infiltrative pulmonary tuberculosis. The action of the oil is mainly due to the antimicrobial activity of its volatile constituents (Shkurupii *et al.*, 2002). Cinnamon and clove oils also showed an inhibition to different Gram (+)-ve and Gram (−)-ve pathogenic bacteria from the vapor phase (Lopez *et al.*, 2005). Aroma inhalation of lavender, peppermint, rosemary and clary-sage essential oils can significantly decrease symptoms associated with anxiety and stress. Inhalation of essential oils can also modulate sympathetic activity in normal adults: for example, the inhalation of pepper, estragon, fennel or grapefruit essential oils resulted in 1.5- to 2.5-fold increase in relative sympathetic activity. In contrast, fragrance inhalation of rose oil or patchouli oil caused a 40% decrease in relative sympathetic activity. On a hormonal level, inhalation of pepper oil induced a 1.7-fold increase in plasma adrenaline concentration compared with the resting state, while inhalation of rose oil caused a 30% decrease in adrenaline concentration (Haze *et al.*, 2002). The rise in rat plasma adrenocorticotrophic hormone caused by stress was significantly reduced by inhalation of chamomile essential oil (Yamada *et al.*, 1996). The same effect can be achieved by the intraperitoneal injection of diazepam, a synthetic tranquillizer. The mode of action of Chamomile essential oil is at least in part via benzodiazepine-sensitive receptors, probably GABA. Other essential oils also have sedative properties upon inhalation (Buchbauer *et al.*, 1992, 1993).

Inhalation of the volatile fractions of lavender and monarda essential oils (0.1–0.2 mg/m³ air) reduced the cholesterol content in the aorta and also atherosclerotic plaques (Nikolaevskii *et al.*, 1990), but had no effect on the content of cholesterol in the blood.

## Massage

Inflammatory diseases, such as allergy, rheumatism and arthritis are often alleviated using essential oil massage therapy (Maruyama *et al.*, 2005; Lawless, 1997). Allergic symptoms can be suppressed by tea tree oil (Brand *et al.*, 2002a; Koh *et al.*, 2002), lavender oil (Kim and Cho, 1999) and the volatile constituent, terpenene-4-ol (Hart *et al.*, 2000). This action is mainly due to the suppression of histamine release (Brand *et al.*, 2002b) and cytokine production (Brand *et al.*, 2001). Cutaneous delivery of geranium essential oil using massage can suppress the inflammatory symptoms with neutrophil accumulation and edema (Maruyama *et al.*, 2005). A lavender fragranced cleansing gel had a significant transient effect of improving mood and making people feel more relaxed (Field *et al.*, 2005). Aromatic materials, topically applied, showed positive effects on lung mucus clearance in patients with chronic airway obstruction (Hasani *et al.*, 2003). Even foot soaking in warm water containing lavender essential oil followed by reflexology treatment with jojoba oil containing lavender, appeared to be effective for alleviating fatigue in terminally ill cancer patients (Kohara *et al.*, 2004). Massage therapy using essential oil can be useful in the treatment for people suffering from dementia. The term 'dementia' is used to describe the symptoms that occur when the brain is affected by specific diseases and conditions, including Alzheimer's disease, stroke and other rarer conditions. Symptoms of dementia include loss of memory, confusion and problems with speech and understanding. Preliminary reports have indicated positive effects of massage therapy using selected essential oils for managing behavioral and psychological symptoms in dementia. The essential oil of *Melissa officinalis* (lemon balm) applied cutaneously in a lotion to patients with severe dementia was found to be an effective treatment (Ballard *et al.*, 2002). The potential efficiency of massage therapy with essential oils to decrease agitation in patients suffering dementia raise the question of whether inhalation of the essential oil or its cutaneous delivery through massage is responsible for the alleviative effect. Snow *et al.* (2004) indicated that inhalation of lavender essential oil did not decrease agitation in severely demented patients and a similar result had previously been reported by Holmes *et al.* (2002). Cutaneous application of the essential oil through massage may therefore be necessary to achieve the alleviative effect in patients with dementia.

Care should be taken when dealing with essential oils in massage. Some essential oils have the potential to be toxic (Prashar *et al.*, 2004; Hayes and Markovic, 2003), while others initiate allergic reactions when applied to the skin via massage (Veien *et al.*, 2004; Schnuch *et al.*, 2004; Crawford *et al.*, 2004; Maddocks-Jennings, 2004; Scardamaglia *et al.*, 2003; Mozelsio *et al.*, 2003; Bleasel *et al.*, 2002; Vilaplana and Romaguera, 2002; Romaguera and Vilaplana, 2000). These allergic reactions arise from certain constituents, e.g. benzyl alcohol, cinnamyl alcohol, eugenol, isoeugenol, hydroxycitronellal, geraniol and many others (European Parliament, 2002). For this reason, warnings must be printed on the label of essential oils containing these components, and aromatherapy practitioners and massage therapists should be also aware of the potential for these adverse effects – and be equipped to deal with them if they should arise (Maddocks-Jennings and Wilkinson, 2004). At the same time, physicians and other health professionals should be able to differentiate between aesthetic applications of odors and clinical uses of essential oils in order to advise and better inform patients.

## CONCLUSIONS

This review attempts to shed light on the therapeutic potential of essential oils and their aroma volatile constituents in the prevention or therapy of disease. The results reviewed in this article are aimed at attracting the attention of researchers seeking new drugs from natural products as well as those investigating the pharmaceutical diversity of essential oils. The data presented provide a basis for reviving the old art of 'essential oil therapy' based on our modern scientific knowledge of their mode of action, supported by safety issues described here. Thus essential oils and their constituents can hopefully be considered in the future for more clinical evaluations and possible applications, and as adjuvants to current medications.

## Acknowledgement

## REFERENCES

Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaie A. 2004. Pesticides and oxidative stress: a review. *Med Sci Monit* **10**: RA 141–147.

Abdollahi M, Salehnia A, Mortazavi S *et al.* 2003. Antioxidant, antidiabetic, antihyperlipidemic, reproduction stimulatory properties and safety of essential oil of *Satureja Khuzestanica* in rat *in vivo*: a toxicopharmacological study. *Med Sci Monit* **9**: 331–335.

Abramovici A, Rachmuth-Roizman P. 1983. Molecular structure–teratogenicity relationships of some fragrance additives. *Toxicology* **29**: 143–156.

Ahmad H, Tijerina M, Tobola A. 1997. Preferential over-expression of a class MU glutathione S-transferase subunit in mouse liver by myristicin. *Biochem Biophys Res Commun* **236**: 825–828.

Ahn K, Lee C, Choi E, Griffin R, Song C, Park J. 2003. Cytotoxicity of perillyl alcohol against cancer cells is potentiated by hyperthermia. *Int J Radiat Oncol Biol Phys* **57**: 813–819.

Ali B, Blunden, G. 2003. Pharmacological and toxicological properties of *Nigella sativa*. *Phytother Res* **17**: 299–305.

Allahverdiyev A, Duran N, Ozguven M, Koltas S. 2004. Antiviral activity of the volatile oils of *Melissa officinalis* L. against Herpes simplex virus type-2. *Phytomedicine* **11**: 657–661.

Al-Hader A, Hasan, Z, Agel M. 1994. Hyperglycemic and insulin release inhibitory effects of *Rosmarinus officinalis*. *J. Ethnopharmacol* **43**(3): 217–221.

Alviano W, Mendonca-Filho R, Alviano D *et al.* 2005. Antimicrobial activity of *Croton cajucara* Benth linalool-rich essential oil on artificial biofilms and planktonic microorganisms. *Oral Microbiol Immunol* **20**: 101–105.

Amnuaikit C, Ikeuch I, Ogawara K, Higaki K, Kimura T. 2005. Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use. *Int J Pharmacol* **289**: 167–178.

Apitz-Castro R, Cabrera S, Cruz M, Ledezma E, Jain M. 1983. Effects of garlic extract and of three pure components isolated from it on human platelet aggregation, arachidonate metabolism, release reaction and platelet ultrastructure. *Thromb Res* **32**: 155–169.

Apitz-Castro R, Ledezma E, Escalante J, Jain M. 1986. The molecular basis of the antiplatelet action of ajoene: direct interaction with the fibrinogene receptor. *Biochem Biophys Res Commun* **141**: 145–150.

Ariazi E, Satomi Y, Ellis M *et al.* 1999. Activation of the transforming growth factor ß signaling pathway and induction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. *Cancer Res* **59**: 1917–1928.

Armaka M, Papanikolaou E, Sivropoulou A, Arsenakis M. 1999. Antiviral properties of isoborneol, a potent inhibitor of herpes simplex virus type-1. *Antiviral Res* **43**: 79–92.

Azzoli C, Miller V, Ngm K *et al.* 2003. A phase I trial of perillyl alcohol in patients with advanced solid tumors. *Cancer Chemother Pharmacol* **51**: 493–498.

Bailey H, Wilding G, Tutsch K *et al.* 2004. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. *Cancer Chemother Pharmacol* **54**: 368–376.

Balfour J, McTavish D. 1992. Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis. *Drugs Aging* **2**: 487–507.

Ballabenia V, Tognolinia M, Chiavarinia M *et al.* 2004. Novel antiplatelet and antithrombotic activities of essential oil from *Lavandula hybrida* Reverchon 'grosso'. *Phytomedicine* **11**: 596–601.

Ballard C, O'Brien J, Reichelt K, Perry E. 2002. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with *Melissa*. *J Clin Psychiatry* **63**: 553–558. Comment in *J Clin Psychiatry* 2003; **64**: 732; author reply 732.

Baqui A, Kelley J, Jabra-Rizk M, Depaola L, Falkler W, Meiller T. 2001. *In vitro* effects of oral antiseptics human immunodeficiency virus-1 and herpes simplex virus type 1. *J Clin Periodontol* **28**: 610–616.

Bardon S, Foussard V, Fournel S, Loubat A. 2002. Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. *Cancer Lett* **181**: 187–194.

Bardon S, Picard K, Martel P. 1998. Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. *Nutr Cancer* **32**: 1–7.

Barocelli E, Calcina F, Chiavarini M *et al.* 2004. Antinociceptive and gastroprotective effects of inhaled and orally administered *Lavandula hybrida* Reverchon 'Grosso' essential oil. *Life Sci* **76**: 213–223.

Barry B. 1991. Lipid-protein-partitioning theory of skin penetration enhancement. *J Control Rel* **15**: 237–248.

Barter P. 2005. The inflammation: Lipoprotein cycle. *Atherosclerosis Suppl* **6**(2): 15–20.

Benjamin H, Lau M, Padma P, Tadi M, Jeffrey M. 1990. *Allium sativum* (garlic) and cancer prevention. *Nutr Res* **10**: 937–948.

Bergonzelli G, Donnicola D, Porta N, Corthésy-Theulaz I. 2003. Essential oils as components of a diet-based approach to management of *Helicobacter* infection. *Antimicrob Agents Chemother* **47**: 3240–3246.

Birch C, Tachedjian G, Doherty R, Hayes K, Gust, I. 1990. Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. *J Infect Dis* **162**: 731–734.

Bleasel N, Tate B, Rademaker M. 2002. Allergic contact dermatitis following exposure to essential oils. *Australas J Dermatol* **43**: 211–213.

Block E, Ahmad S, Catalfamo J, Jain M, Apitz-Castro R. 1986. Antithrombotic organosulfur compounds from garlic: structural, mechanistic and synthetic studies. *J Am Chem Soc* **108**: 7045–7055.

Bodake H, Panicker K, Kailaje V, Rao V. 2002. Chemopreventive effect of orange oil on the development of hepatic preneoplastic lesions induced by N-nitrosodiethylamine in rats: an ultrastructural study. *Indian J Exp Biol* **40**: 245–251.

Bordia A. 1981. Effect of garlic on blood lipids in patients with coronary heart disease. *Am J Clin Nutr* **34**: 2100–2103.

Bordia T, Mohammed N, Thomson M, Ali M. 1996. An evaluation of garlic and onion as antithrombotic agents. *Prostaglandins Leuko Essent Fatty Acids* **54**: 183–186.

Botsoglou N, Florou-Paneri P, Christaki E, Giannenas I, Spais A. 2004. Performance of rabbits and oxidative stability of muscle tissues as affected by dietary supplementation with oregano essential oil. *Arch Anim Nutr* **58**: 209–218.

Boyce J, Pittet D. 2002. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. *Infect Control Hosp Epidemiol* **23**(S12): S3–S40.

Bozin B, Mimica-Dukic N, Simin N, Anackov G. 2006. Characterization of the volatile composition of essential oils of some Lamiaceae spices and the antimicrobial and antioxidant activities of the entire oils. *J Agric Food Chem* **54**: 1822–1828.

Braddock R, Cadwallader K. 1995. Bioconversion of citrus *d*-limonene. *Fruit Flavors* **596**: 142–148.

Brand C, Ferrante A, Prager R *et al.* 2001. The water-soluble components of the essential oil of *Melaleuca alternifolia* (tea tree oil) suppress the production of superoxide by human monocytes, but not neutrophils, activated *in vitro*. *Inflamm Res* **50**: 213–219.

Brand C, Grimbaldeston M, Gamble J, Finlay-Jones J, Hart P. 2002a. Tea tree oil reduces the swelling associated with the different phase of a contact hypersensitivity response. *Inflamm Res* **51**: 236–244.

Brand C, Townley S, Finlay-Jones J, Hart P. 2002b. Tea tree oil reduces histamine-induced oedema in murine ears. *Inflamm Res* **51**: 283–289.

Broadhurst C, Polansky M, Anderson R. 2000. Insulin-like biological activity of culinary and medicinal plant aqueous extract *in vitro*. *J Agric Food Chem* **48**: 849–852.

Brophy J, Davis N, Southwell I, Stiff I, Williams L. 1989. Gas chromatographic quality control for oil of *Melaleuca* terpinene-4-ol type (Australian tea tree). *J Agric Food Chem* **37**: 1330–1335.

Buchbauer G, Jager W, Jirovetz L, Meyer F, Dietrich H. 1992. Effects of valerian root oil, borneol, isoborneol, bornyl acetate and isobornyl acetate on the motility of laboratory animals (mice) after inhalation. *Pharmazie* **47**: 620–622.

Buchbauer G, Jirovetz L. 1993. Aromatherapie-Definition und discussion uber den stand der forschung (German). *Arstezeitschrift fur Naturheilverfahren* **34**: 259–264.

Buchbauer G, Jirovetz L. 1994. Aromatherapy use of fragrance and essential oils as medicament. *Flavour Fragr J* **9**: 217–222.

Buchbauer G, Jirovetz L, Jager W, Plank C, Dietrich H. 1993. Fragrance compounds and essential oils with sedative effects upon inhalation. *J Pharm Sci* **82**: 660–664.

Buhagiar J, Podesta M, Wilson A, Micallef M, Ali S. 1999. The induction of apoptosis in human melanoma, breast and ovarian cancer cell lines using an essential oil extract from the conifer *Tetraclinis articulate*. *Anticancer Res* **19**: 5435–5443.

Burke Y, Ayoubi A, Werner S *et al.* 2002. Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. *Anticancer Res* **22**: 3127–3134.

Burt S. 2004. Essential oils: their antibacterial properties and potential applications in foods – a review. *Int J Food Microbiol* **94**: 223–253.

Butterfield D, Lauderback C. 2002. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. *Free Radic Biol Med* **32**: 1050–1060.

Calcabrini A, Stringaro A, Toccacieli L *et al.* 2004. Terpinen-4-ol, the main component of *Melaleuca alternifolia* (tea tree) oil inhibits the *in vitro* growth of human melanoma cells. *J Invest Dermatol* **122**: 349–360.

Calvey E, Roach J, Block E. 1994. Supercritical fluid chromatography of garlic (*Allium sativum*) extracts with mass spectrometric identification of allicin. *J Chromatogr Sci* **32**: 93–96.

Campbell W, Gammon D, Smith P, Abrahams M, Purves T. 1997. Composition and antimalarial activities *in vitro* of the essential oil of *Tetradenia riparia*. *Planta Med* **63**: 270–272.

Candan F, Unlu M, Tepe B *et al.* 2003. Antioxidant and antimicrobial activity of the essential oil and methanol extracts of *Achillea millefolium* subsp. *millefolium* Afan. (Asteraceae). *J Ethnopharmacol* **87**: 215–220.

Carnesecchi S, Bradaia A, Fischer B *et al.* 2002a. Perturbation by geraniol of cell membrane permeability and signal transduction pathways in human colon cancer cells. *J Pharmacol Exp Ther* **303**: 711–715.

Carnesecchia S, Bras-Gonc R, Bradaiac A *et al.* 2004. Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts. *Cancer Lett* **215**: 53–59.

Carnesecchi S, Langley K, Exinger F, Gosse F, Raul F. 2002b. Geraniol, a component of plant essential oils, sensitizes human colonic cancer cell to 5-fluorouracil treatment. *J Pharmacol Exp Ther* **301**: 625–630.

Carson F, Hammer A, Riley V. 2006. *Melaleuca alternifolia* (Tea Tree) oil: a review of antimicrobial and other medicinal properties. *Clin Microbiol Rev* **19**: 50–62.

Carson C, Riley T. 1995. Toxicity of the essential oil of *Melaleuca alternifolia* or tea tree oil. *J Toxicol Clin Toxicol* **33**: 193–195.

Cavalieri E, Mariotto S, Fabrizi C *et al.* 2004. *a*-Bisabolol, a nontoxic natural compound, strongly induces apoptosis in glioma cells. *Biochem Biophys Res Commun* **315**: 589–594.

Charles C, Mostler K, Bartels L, Mankodi S. 2004. Comparative antiplaque and antigingivitis effectiveness of a chlorhexidine and an essential oil mouthrinse: 6-month clinical trial. *J Clin Periodontol* **31**: 878–884.

Chen C, Pung D, Leong V *et al.* 2004. Induction of detoxifying enzymes by garlic organosulfur compounds through transcription factor NRF2: effect of chemical structure and stress signals. *Free Radic Biol Med* **37**: 1578–1590.

Chen X, Yano Y, Hasuma T, Yoshimata T, Yinna W, Otani S. 1999. Inhibition of farnesyl protein transferase and P21ras membrane association by d-limonene in human pancreas tumor cells *in vitro*. *Chin Med Sci J* **14**: 138–144.

Cheng J, Chang G, Wu W. 2001. A controlled clinical study between hepatic arterial infusion with embolized *Curcuma* aromatic oil and chemical drugs in treating primary liver cancer. *Zhongguo Zhong Xi Yi Jie He Za Zhi* (*Chin J Integr Trad Western Med*) **21**: 165–167. Abstract is in English and available on www.pubmed.org

Clark S, Perman S, Sahin M, Jenkins G, Elegbede J. 2002. Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest. *Leukemia* **16**: 213–222.

Clark S, Zhong L, Filiault D *et al.* 2003. Anti-leukemia effect of perillyl alcohol in Bcr/Abl-transformed cells indirectly inhibits signaling through Mek in a Ras- and Raf-independent fashion. *Clin Cancer Res* **9**: 4494–4504.

Cornwell A, Barry W. 1991. The effects of a series of homologous terpene alcohols on the lipid structure of human stratum corneum as assessed by differential scanning calorimetry. In *Prediction of Percutaneous Penetration*, Scott RC, Guy H, Hadgraft J, Bodde E (eds), Vol. 2. IBC Technical Services: London, 394–400.

Cornwell A, Barry W. 1994. Sesquiterpene components of volatile oils as skin penetration enhancers for the hydrophilic permeant 5-fluorouracil. *J Pharm Pharmacol* **46**: 261–269.

Corson S. 1993. Clinical experience with Systen, a new transdermal form of hormone replacement therapy. *Int J Fertil Menopausal Stud* **38** (Suppl. 1): 36–44.

Crawford G, Sciacca J, James W. 2004. Tea tree oil: cutaneous effects of the extracted oil of *Melaleuca alternifolia*. *Dermatitis* **15**: 59–66.

Dadalioglu I, Evrendilek G. 2004. Chemical compositions and antibacterial effects of essential oils of Turkish oregano (*Origanum minutiflorum*), bay laurel (*Laurus nobilis*), Spanish lavender (*Lavandula stoechas* L.), and fennel (*Foeniculum vulgare*) on common foodborne pathogens. *J Agric Food Chem* **52**: 8255–8260.

Daugherty A, Roselaar S. 1995. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. *Cardiovasc Res* **29**: 297–231.

Deans S, Ritchie G. 1987. Antibacterial properties of plant essential oils. *Int J Food Microbiol* **5**: 165–180.

De Angelis L. 2001. Brain tumors. *N Engl J Med* **344**: 114–123.

De Logu A, Loy G, Pellerano M, Bonsignore L, Schivo M. 2000. Inactivation of HSV-1 and HSV-2 and prevention of cell-to-cell virus spread by *Santolina insularis* essential oil. *Antiviral Res* **48**: 177–185.

Del Toro-Arreola S, Flores-Torales E, Torres-Lozano C *et al.* 2005. Effect of D-limonene on immune response in BALB/c mice with lymphoma. *Int Immunopharmacol* **5**: 829–838.

De Sousa A, Alviano D, Blank A, Alves P, Alviano C, Gattass C.

2004. *Melissa officinalis* L. essential oil: antitumoral and antioxidant activities. *J Pharm Pharmacol* **56**: 677–681.

Deyama T, Horiguchi T. 1971. Studies on the components of essential oil of clove (*Eugenia caryophylatta Thumberg*). *Yakugaku Zasshi* **91**: 1383–1386. (English abstract is available on www.pubmed.org)

Dryden M, Dailly S, Crouch M. 2004. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. *J Hosp Infect* **58**: 86–87.

Duetz W, Bouwmeester H, van Beilent J, Witholt B. 2003. Biotransformation of limonene by bacteria, fungi, yeast and plants. *Appl Microbiol Biotechnol* **61**: 269–277.

Edris A, Shalaby A, Fadel H. 2003. Evaluation of a chemotype of spearmint (*Mentha spicata* L.) growing in Siwa Oasis, Egypt. *Eur Food Technol* **218**: 74–78.

Elegbede J, Flores R, Wang C. 2003. Perillyl alcohol and perillaldehyde induced cell cycle arrest and cell death in BroTo and A549 cells cultured *in vitro*. *Life Sci* **73**: 2831–2840.

El-Kattan A, Asbill C, Kim N, Michniak B. 2001. The effects of terpene enhancers on the percutaneous permeation of drugs with different lipophilicities. *Int J Pharm* **215**: 229–240.

Elson C. 1995. Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease. *J Nutr* **125**: 1666S–1672S.

European Parliament. 2002. New 7th Amendment to Annex III – Part 1, (Directive 76/768/EEC).

Fahad A, Stepher L. 1996. New anti-herpes virus agents. Their targets and therapeutics. *Potent Drugs* **52**: 17–32.

Fang J, Leu Y, Hwang T, Cheng H. 2004. Essential oils from Sweet Basil (*Ocimum basilicum*) as novel enhancers to accelerate transdermal drug delivery. *Biol Pharm Bull* **27**: 1819–1825.

FAO/WHO. 2003. *Summary of Evaluations Performed by the Joint FAO/WHO Expert Committee on Food Additives*. International Program on Chemical Safety (IPCS) INCHEM. web site: http://www.inchem.org/documents/jecfa/jeceval/jec_384.htm

Field T, Diego M, Hernandez-Reif M *et al.* 2005. Lavender fragrance cleansing gel effects on relaxation. *Int J Neurosci* **115**: 207–222.

Fitzgerald D 2001. Vascular biology of thrombosis. The role of platelet–vessel wall adhesion. *Neurology* **57**: S1–S4.

Garcia C, Talarico L, Almeida N, Colombres S, Duschatzky C, Damonte B. 2003. Virucidal activity of essential oils from aromatic plants of San Luis, Argentina. *Phytother Res* **17**: 1073–1075.

Gardner P. 1997. Superoxide-driven aconitase FE-S center cycling. *Biosci Rep* **17**: 33–/42.

Gaysinsky S, Davidson P, Bruce D, Weiss J. 2005. Growth inhibition of *Escherichia coli* O157:H7 and *Listeria monocytogenes* by carvacrol and eugenol encapsulated in surfactant micelles. *J Food Prot* **68**: 2559–2566.

Ghafourian T, Zandasrar P, Hamishehkar H, Nokhodchi A. 2004. The effect of penetration enhancers on drug delivery through skin: a QSAR study. *J Cont Release* **99**: 113–125.

Gould M. 1995. Prevention and therapy of mammary cancer by monoterpenes. *J Cell Biochem* Suppl **22**: 139–144.

Gould M. 1997. Cancer chemoprevention and therapy by monoterpenes. *Environ Health Perspect* **105** (Suppl 4): 977–979.

Grassmann J, Hippeli S, Spitzenberger R, Elstner F. 2005. The monoterpene terpinolene from the oil of *Pinus mugo* L. in concert with $\alpha$-tocopherol and beta-carotene effectively prevents oxidation of LDL. *Phytomedicine* **12**: 416–423.

Grassmann J, Hippeli S, Vollmann R, Elstner E. 2003. Antioxidative properties of the essential oil from *Pinus mugo*. *J Agric Food Chem* **51**: 7576–7582.

Greenwald P, Milner J, Anderson D, McDonald S. 2002. Micronutrients in cancer chemoprevention. *Cancer Metastasis Rev* **21**: 217–230.

Guang L, Feng B, Zhan L, Yu Z. 2003. D-limonene induces apoptosis of gastric cancer cells. *Zhonghua Zhong Liu Za Zhi* (*Chin J Oncol*) **25**: 325–727 (the abstract is in English and available on www.pubmed.org

Guang L, Li-Bin Z, Bing-An F, Ming-Yang Q, Li-Hua Y, Ji-Hong X. 2004. Inhibition of growth and metastasis of human gastric cancer implanted in nude mice by d-limonene. *World J Gastroenterol* **10**: 2140–2144.

Guedes D, Silva D, Barbosa-Filho J, de Medeiros I. 2004. Endothelium-dependent hypotensive and vasorelaxant effects of the essential oil from aerial parts of *Mentha x villosa* in rats. *Phytomedicine* **1**: 490–497.

Guenther E. 1950. In *The Essential Oil* vol. IV. D.Van Nostrand: New York.

Guyton K, Kensler T. 2002. Prevention of liver cancer. *Curr Oncol Rep* **4**: 464–470.

Halliwell B, Gutteridge J. 1990. The antioxidants of human extracellular fluids. *Arch Biochem Biophys* **280**: 1–8.

Hamada S, Kamada M, Furumoto H, Hirao T, Aono T. 1994. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy. *Gynecol Oncol* **52**: 313–319.

Hammer A, Carson F, Riley V, Nielsen B. 2006. A review of the toxicity of *Melaleuca alternifolia* (tea tree) oil. *Food Chem Toxicol* **44**(5): 616–625.

Harman D. 1995. Role of antioxidant nutrients in ageing: overview. *Age* **18**: 51–62.

Hart P, Brand C, Carson C, Riley T, Prager R, Finlay-Jones J. 2000. Terpinen-4-ol the main component of the essential oil of *Melaleuca alternifolia* (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. *Inflamm Res* **49**: 619–626.

Hasani A, Pavia D, Toms N, Dilworth P, Agnew E. 2003. Effect of aromatics on lung mucociliary clearance in patients with chronic airways obstruction. *J Altern Complement Med* **9**: 243–249.

Hayes A, Markovic B. 2003. Toxicity of Australian essential oil *Backhousia citriodora* (lemon myrtle). Part 2. Absorption and histopathology following application to human skin. *Food Chem Toxicol* **41**: 1409–1416.

Haze S, Sakai K, Gozu Y. 2002. Effects of fragrance inhalation on sympathetic activity in normal adults. *Jpn J Pharmacol* **90**: 247–253.

Henderson C, Smith A, Ure J, Brown K, Bacon E, Wolf C. 1998. Increased skin tumorigenesis in mice lacking $\pi$-class glutathione S-transferase. *Proc Natl Acad Sci USA* **95**: 5275–5280.

Hennessy B, Joyce A. 2004. A survey of preprocedural antiseptic mouth rinse use in Army dental clinics. *Mil Med* **169**: 600–603.

Higaki K, Amnuaikit C, Kimura T. 2003. Strategies for overcoming the stratum corneum: chemical and physical approaches. *Am J Drug Deliv* **1**: 187–214.

Holmes C, Hopkins V, Hensford C, MacLaughlin V, Wilkinson D, Rosenvinge H. 2002. Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. *Int J Geriat Psychiatry* **17**: 305–308.

Hossain S, Aoshima H, Koda H, Kiso Y. 2004. Fragrances in oolong tea that enhance the response of GABAA receptors. *Biosci Biotechnol Biochem* **68**: 1842–1848.

Howard B, Donna L, Harris S *et al.* 2002. A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer. Eastern Cooperative Oncology Group Study E2E96. *Gynecol Oncol* **85**: 464–468.

Huang Y, Fang J, Hung C, Wu P, Tsai Y. 1999. Cyclic monoterpene extract from cardamom oil as a skin permeation enhancer for indomethacin: *in vitro* and *in vivo* studies. *Biol Pharm Bull* **22**: 642–646.

Hulin V, Mathot A, Mafart P. 1998. Les propriétés antimicrobiennes des huiles essentielles et composés d'arômes. *Sci Aliments* **18**: 563–582.

Ibrel B, Winkler G, Knobloch K. 1990. Products of allicin transformation: Ajoene and dithiins. Characterization and their determination by HPLC. *Planta Med* **56**: 202–211.

Imai H, Osawa K, Uasuda H, Hamashima H, Arai T, Sasatsu M. 2001. Inhibition by the essential oils of peppermint and spearmint of the growth of pathogenic bacteria. *Microbios* **106**(S1): 31–39.

Iwalokun B, Gbenle G, Adewole T, Smith S, Akinsinde K, Omonigbehin E. 2003. Effects of *Ocimum gratissimum* L. essential oil at subinhibitory concentrations on virulent and multidrug-resistant *Shigella* strains from Lagos, Nigeria. *APMIS* **111**: 477–482.

Jiri R, Parija T, Das B. 1999. d-Limonene chemoprevention of hepatocarcinogenesis in AKR mice: inhibition of c-jun and c-myc. *Oncol Rep* **6**: 1123–1127.

Jirovetz L, Buchbauer G, Denkova Z *et al.* 2005. Antimicrobial testings and gas chromatographic analysis of pure oxygenated monoterpenes 1,8-cineol, $\alpha$-terpineol, terpene-4-ol and

camphor as well as target compounds in essential oils of pine (*Pinus pinaster*), rosemary (*Rosmarinus officinalis*) and tee tree (*Melaleuca alternifolia*). *Sci Pharm* **73**: 27–39.

Juergens U, Stober M, Vetter H. 1998. Inhibition of cytokine production and arachidonic acid metabolism by eucalyptol (1,8-cineole) in human blood monocytes *in vitro*. *Eur J Med Res* **3**: 508–510.

Juven J, Kanner J, Schved F, Weisslowicz H. 1994. Factors that interact with antimicrobial action of thyme essential oil and its active constituents. *J Appl Bacteriol* **76**: 626–631.

Kagawa D, Jokura H, Ochiai R, Tokimitsu I, Tsubone H. 2003. The sedative effects and mechanism of action of cedrol inhalation with behavioral pharmacological evaluation. *Planta Med* **69**: 637–641.

Kaji I, Tatsuta M, Iishi H, Baba M, Inoue A, Kasugai H. 2001. Inhibition by d-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve p21(ras) plasma membrane association. *Int J Cancer* **93**: 441–444.

Kalpoutzakis E, Aligiannis N, Mentis A, Mitaku S, Charvala C. 2001. Composition of the essential oil of two nepeta species and *in vitro* evaluation of their activity against *Helicobacter pylori*. *Planta Med* **67**: 880–883.

Kanikkannan N, Andega S, Burton S, Babu R, Singh M. 2004. Formulation and *in vitro* evaluation of transdermal patches of melatonin. *Drug Dev Ind Pharm* **30**: 205–212.

Kelloff GJ, Boone CW, Crowell J *et al.* 1996. New agents for cancer chemoprevention. *J Cell Biochem Suppl* **26**: 1–28.

Kelly D. 1998. The physiology and metabolism of the human gastric pathogen *Helicobacter pylori*. *Adv Microb Physiol* **40**: 137–189.

Kendler B. 1987. Garlic (*Allium sativum*) and onion (*Allium cepa*): a review of their relationship to cardiovascular disease. *Prevent Med* **16**: 670–685.

Kim H, Chen F, Wu C, Wang X, Chung H, Jin Z. 2004. Evaluation of antioxidant activity of Australian tea tree (*Melaleuca alternifolia*) oil and its components. *J Agric Food Chem* **52**: 2849–2854.

Kim H, Cho S. 1999. Lavender oil inhibits immediate-type allergic reaction in mice and rats. *J Pharm Pharmacol* **51**: 221–226.

Kim J, Marshall M, Wei C. 1995 Antimicrobial activity of some essential oils components against five foodborne pathogens. *J Agric Food Chem* **43**: 2839–2845.

Koh K, Pearce A, Marshma, G, Finlay-Jones J, Hart P. 2002. Tea tree oil reduces histamine-induced skin inflammation. *Br J Dermatol* **147**: 1212–1217.

Kohara H, Miyauchi T, Suehiro Y, Ueoka H, Takeyama H, Morita T. 2004. Combined modality treatment of aromatherapy, footsoak, and reflexology relieves fatigue in patients with cancer. *J Palliat Med* **7**: 791–796.

Koo B, Lee S, Ha J, Lee D. 2004. Inhibitory effects of the essential oil from SuHeXiang Wan on the central nervous system after inhalation. *Biol Pharm Bull* **27**: 515–519.

Koo B, Park K, Ha J, Park J, Lim J, Lee D. 2003. Inhibitory effects of the fragrance inhalation of essential oil from *Acorus gramineus* on central nervous system. *Biol Pharm Bull* **26**: 978–982.

Kulisic T, Radonic A, Katalinic V, Milos M. 2004. Analytical, nutritional and clinical methods use of different methods for testing antioxidative activity of oregano essential oil. *Food Chem* **85**: 633–640.

Lahlou S, Interaminense F, Leal-Cardoso J, Morais S, Duarte G. 2004. Cardiovascular effects of the essential oil of *Ocimum gratissimum* leaves in rats: role of the autonomic nervous system. *Clin Exp Pharmacol Physiol* **1**: 219–225.

Lahlou S, Leal-Cardoso J, Duarte G. 2003 Antihypertensive effects of the essential oil of *Alpinia zerumbet* and its main constituent, terpinen-4-ol, in DOCA-salt hypertensive conscious rats. *Fundam Clin Pharmacol* **17**: 323–330.

Larson E. 2001. Hygiene of the skin: when is clean too clean? *Emerg Infect Dis* **7**: 225–230.

Lawless J. 1997. *The Complete Illustrated Guide to Aromatherapy*. Element Books: Dorset.

Lawson L, Ransom D, Hughes B. 1992. Inhibition whole blood platelet aggregation by compounds in garlic clove extract and commercial garlic products. *Thromb Res* **65**: 141–156.

Lee B, Kim J, Jung J *et al.* 2005. Myristicin-induced neurotoxicity in human neuroblastoma SK-N-SH cells. *Toxicol Lett* **157**: 49–56.

Li Y, Li M, Wang L, Jiang Z, Li W, Li H. 2004. Induction of apoptosis of cultured hepatocarcinoma cell by essential oil of *Artemisia Annul* L. *Sichuan Da Xue Xue Bao Yi Xue Ban* (*J West China Univ Med Sci*) **35**: 337–339. Abstract is in English and available on www.pubmed.org

Liston B, Nines R, Carlton P *et al.* 2003. Perillyl alcohol as a chemopreventive agent in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. *Cancer Res* **63**: 2399–2403.

Liu G, Oettel K, Bailey H *et al.* 2003. Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. *Invest New Drugs* **21**: 367–372.

Lopez P, Sanchez C, Batlle R, Nerin C. 2005. Solid- and vapor-phase antimicrobial activities of six essential oils: susceptibility of selected foodborne bacterial and fungal strains. *J Agric Food Chem* **53**: 6939–6946.

Loutrari H, Hatziapostolou M, Skouridou V *et al.* 2004. Perillyl alcohol is an angiogenesis inhibitor. *J Pharmacol Exp Ther* **311**: 568–575.

Maddocks-Jennings W. 2004. Critical incident: idiosyncratic allergic reactions to essential oils. *Complement Ther Nurs Midwifery* **10**: 58–60.

Maddocks-Jennings W, Wilkinson J. 2004. Aromatherapy practice in nursing: literature review. *J Adv Nurs* **48**: 93–103.

Makheja A, Bailey J. 1990. Antiplatelet constituents of garlic and onion. *Agents Actions* **29**: 360–364.

Maltzman H, Christou M, Gould M, Jefcoate C. 1991. Effects of monoterpenoids on *in vivo* DMBA-DNA adduct formation and on phase I hepatic metabolizing enzymes. *Carcinogenesis* **12**: 2081–2090.

Mans D, Grivicich I, Peters G, Schwartsmann G. 1999. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. *Eur J Cancer* **35**: 1851–1861.

Mansour M, Ginawi O, El-Hadiyah T, El-Khatib A, Al-Shabanah O, Al-Sawaf H. 2001. Effects of volatile oil constituents of *Nigella sativa* on carbon tetrachloride-induced hepatotoxicity in mice: evidence for antioxidant effects of thymoquinone. *Res Commun Mol Pathol Pharmacol* **110**: 239–251.

Maruyama N, Sekimoto Y, Ishibashi H *et al.* 2005. Suppression of neutrophil accumulation in mice by cutaneous application of geranium essential oil. *J Inflamm* **2**: 1–11.

Mathew B, Daniel R, Augusti K. 1996. Hypolipidemic effect of garlic protein substituted for casein in diet of rats compared to those of garlic oil. *Indian J Exp Biol* **34**: 337–340.

Mau J, Laib E, Wang N, Chen C, Chang C, Chyau C. 2003. Composition and antioxidant activity of the essential oil from *Curcuma zedoaria*. *Food Chem* **82**: 583–591.

May J, Chan C, King A, Williams L, French G. 2000. Time-kill studies of tea tree oils on clinical isolates. *J Antimicrob Chemother* **45**: 639–643.

Mazzaro D. 2000. Orange oil, *d*-limonene market unsettled due to Brazilian delay. *Chem Marketing Rep* **258**: 18–22.

McCord J. 2000. The evolution of free radicals and oxidative stress. *Am J Med* **108**: 652–659.

McDonald J, Marchand M, Langer R. 2004. Improving upon the *in vitro* biological activity of antithrombotic disulfides. *Blood Coagulation Fibrinolysis* **15**: 447–450.

McNulty C, Wilson M, Havinga W, Johnston B, O'Gara E Maslin D. 2001. A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with *Helicobacter pylori*. *Helicobacter* **6**: 249–253.

Meadows S, Mulkerin D, Berlin J *et al.* 2002. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. *Int J Gastrointest Cancer* **32**: 125–128.

Mehta M, Tome W, Olivera G. 2000. Radiotherapy for brain tumors. *Curr Oncol Rep* **2**: 438–444.

Messager S, Hammer K, Carson C, Riley T. 2005a. Assessment of the antibacterial activity of tea tree oil using the European EN 1276 and EN 12054 standard suspension tests. *J Hosp Infect* **59**: 113–125.

Messager S, Hammer K, Carson C, Riley T. 2005b. Effectiveness of hand-cleansing formulations containing tea tree oil assessed *ex vivo* on human skin and *in vivo* with volunteers using European standard EN 1499. *J Hosp Infect* **59**: 220–228.

Miguel G, Simones M, Figueiredo A, Barroso J, Pedro L, Carvalho L. 2004. Composition and antioxidant activities of

the essential oils of *Thymus caespititius*, *Thymus camphoratus* and *Thymus mastichina*. *Food Chem* **86**: 183–188.

Milner JA. 2001. A historical perspective on garlic and cancer. *J Nutr* **131**: 1027S–1031S.

Mimica-Dukic N, Bozin B, Sokovic M, Mihajlovic B, Matavulj M. 2003. Antimicrobial and antioxidant activities of three *Mentha* species essential oils. *Planta Med* **69**: 413–419.

Mimica-Dukic N, Bozin B, Sokovic M, Simin N. 2004. Antimicrobial and antioxidant activities of *Melissa officinalis* L. (Lamiaceae) essential oil. *J Agric Food Chem* **52**: 2485–2489.

Minami M, Kita M, Nakaya T, Yamamoto T, Kuriyama H, Imanishi J. 2003. The inhibitory effect of essential oils on herpes simplex virus type-1 replication *in vitro*. *Microbiol Immunol* **47**: 681–684.

Mondello L, Dugo P, Bartle D. 1995 Automated HPLC-HRGC: A powerful method for essential oil analysis. Part V. Identification of terpene hydrocarbons of bergamot, lemon, mandarin, sweet orange, bitter orange, grapefruit, Clementine and Mexican lime oils by coupled HPLC-HRGC-MS (ITD). *Flavour Fragr J* **10**: 33–42.

Monti D, Chetoni P, Burgalassi S, Najarro M, Fabrizio M, Boldrini E. 2002. Effect of different terpene-containing essential oils on permeation of estradiol through hairless mouse skin. *Int J Pharm* **237**: 209–214.

Moon C, Jung Y, Kim M, Lee S, Baik E, Park S. 2000. Mechanism for antiplatelet effect of *Allium cepa* in rat and human platelet. *Prostaglandins Leukot Essent Fatty Acids* **62**: 277–283.

Morita T, Jinno K, Kawagishi H *et al.* 2003. Hepatoprotective effect of myristicin from nutmeg (*Myristica fragrans*) on lipopolysaccharide/d-galactosamine-induced liver injury. *J Agric Food Chem* **51**: 1560–1565.

Morse M, Stoner G. 1993. Cancer chemoprevention: principle and prospects. *Carcinogenesis* **14**: 1737–1746.

Moteki H, Hibasami H, Yamada Y, Katsuzaki H, Imai K, Komiya T. 2002. Specific induction of apoptosis by 1,8-cineole in two human leukemia cell lines, but not a in human stomach cancer cell line. *Oncol Rep* **9**: 757–760.

Mozelsio N, Harris K, McGrath K, Grammer L. 2003. Immediate systemic hypersensitivity reaction associated with topical application of Australian tea tree oil. *Allergy Asthma Proc* **24**: 73–75.

Mulder T, Verspaget H, Sier C *et al.* 1995. Glutathione S-transferase-pi in colorectal tumors is predictive for overall survival. *Cancer Res* **55**: 2696–2702.

Naderi G, Asgary S, Ani M, Sarraf-Zadegan N, Safari M. 2004. Effect of some volatile oils on the affinity of intact and oxidized low-density lipoproteins for adrenal cell surface receptors. *Mol Cell Biochem* **267**: 59–66.

Naikoba S, Hayward A. 2001. Effectiveness of interventions aimed at increasing handwashing in healthcare workers – a systematic review. *J Hosp Infect* **47**: 173–180.

Nakamura Y, Miyamoto M, Murakami A, Ohigashi H, Osawa T, Uchida K. 2003. A phase II detoxification enzyme inducer from lemongrass: identification of citral and involvement of electrophilic reaction in the enzyme induction. *Biochem Biophys Res Commun* **302**: 593–600.

Narishetty S, Panchagnula R. 2004. Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. *J Control Rel* **95**: 367–379.

National Toxicology Program (1983) Carcinogenesis Studies of Eugenol (CAS No. 97-53-0) in F344/N Rats and B6C3F$_1$ Mice (Feed Studies). Technical report 223. Web site: http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr223.pdf and http://ntp.niehs.nih.gov/index.cfm?objectid=0706392B-FC21-9098-2E10402B9BAC8AF1

National Toxicology Program. 2003. NTP technical report (505) on the toxicology and carcinogenesis studies of citral (microencapsulated) (CAS NO. 5392-40-5), in F344/N RATS and B6C3F1 mice (feed studies). http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr505.pdf

Nevas M, Korhonen A, Lindstrom M, Turkki P, Korkeala H. 2004. Antibacterial efficiency of Finnish spice essential oils against pathogenic and spoilage bacteria. *J Food Prot* **67**: 199–202.

Nguefack J, Budde B, Jakobsen M. 2004. Five essential oils from aromatic plants of Cameroon: their antibacterial activity and ability to permeabilize the cytoplasmic membrane of *Listeria innocua* examined by flow cytometry. *Lett Appl Microbiol* **39**: 395–400.

Nikolaevskii V, Kononova N, Pertsovskii A, Shinkarchuk I. 1990. Effect of essential oils on the course of experimental atherosclerosis. *Patol Fiziol Eksp Te* **5**: 52–53 (Article in Russian, abstract in English available on www.pubmed.org).

Nykanen I. 1986. High resolution gas chromatographic-mass spectrometric determination of the flavor composition of marjoram (*Origanum mariorama L.*) cultivated in Finland. *Z Lebensm Unters Forsch* **182**: 267–272.

O'Gara E, Hill D, Maslin D. 2000. Activities of garlic oil, garlic powder, and their diallyl constituents against *Helicobacter pylori*. *Appl Environ Microbiol* **66**: 2269–2273.

Omolo M, Okinyo D, Ndiege I, Lwande W, Hassanali A. 2004. Repellency of essential oils of some Kenyan plants against *Anopheles gambiae*. *Phytochemistry* **65**: 2797–2802.

Opdyke DJ. 1974–1976. Monographs on fragrance raw materials. *Food Cosmet Toxicol* 12–14 Supplements.

Orive G, Hernandez R, Gascon A, Dominguez-Gil A, Pedraz J. 2003. Drug delivery in biotechnology: present and future. *Current Opin Biotech* **14**: 659–664.

Ouhayoun JP. 2003. Penetrating the plaque biofilm: impact of essential oil mouthwash. *J Clin Periodontol* **30**(S5): 10–12.

Ozbek H, Ugras S, Dulger H *et al.* 2003. Hepatoprotective effect of *Foeniculum vulgare* essential oil. *Fitoterapia* **74**: 317–319.

Panchagnula R, Desu H, Jain A, Khandavilli S. 2004. Effect of lipid bilayer alteration on transdermal delivery of a high-molecular-weight and lipophilic drug: studies with paclitaxel. *J Pharm Sci* **93**: 2177–2183.

Papageorgiou G, Botsoglou N, Govaris A, Giannenas I, Iliadis S, Botsoglou E. 2003. Effect of dietary oregano oil and alpha-tocopheryl acetate supplementation on iron-induced lipid oxidation of turkey breast, thigh, liver and heart tissues. *J Anim Physiol Anim Nutr (Berl)* **87**: 324–335.

Parija T, Das B. 2003. Involvement of YY1 and its correlation with c-myc in NDEA induced hepatocarcinogenesis, its prevention by d-limonene. *Mol Biol Rep* **30**: 41–46.

Penalver P, Huerta B, Borge C, Astorga R, Romero R, Perea A. 2005. Antimicrobial activity of five essential oils against origin strains of the Enterobacteriaceae family. *APMIS* **113**: 1–6.

Prashar A, Locke I, Evans C. 2004. Cytotoxicity of lavender oil and its major components to human skin cells. *Cell Prolif* **37**: 221–229.

Primo V, Rovera M, Zanon S *et al.* 2001. Determination of the antibacterial and antiviral activity of the essential oil from *Minthostachys verticillata* (Griseb.) Epling. *Rev. Argent Microbiol* **33**: 113–117.

Puatanachokchai R, Kishida H, Denda A *et al.* 2002. Inhibitory effects of lemon grass (*Cymbopogon citratus*, Stapf) extract on the early phase of hepatocarcinogenesis after initiation with diethylnitrosamine in male Fischer 344 rats. *Cancer Lett* **183**: 9–15.

Rajesh D, Howard P. 2003. Perillyl alcohol mediated radiosensitization via augmentation of the Fas pathway in prostate cancer cells. *Prostate* **57**: 14–23.

Rajesh D, Stenzel R, Howard S. 2003. Perillyl alcohol as a radio-/chemosensitizer in malignant glioma. *J Biol Chem* **278**: 35968–35978.

Reichling J, Fitzi J, Hellmann K, Wegener T, Bucher S, Saller R. 2004. Topical tea tree oil effective in canine localised pruritic dermatitis – a multi-centre randomized double-blind controlled clinical trial in the veterinary practice. *Dtsch Tierarztl Wochenschr* **111**: 408–414.

Ren Z, Gould M. 1998. Modulation of small G protein isoprenylation by anticancer monoterpenes in *in situ* mammary gland epithelial cells. *Carcinogenesis* **19**: 827–832.

Rendu F, Daveloose D, Debouzy J *et al.* 1989. Ajoene, the antiplatelet compound derived from garlic, specifically inhibits platelet release reaction by affecting the plasma membrane internal microviscosity. *Biochem Pharmacol* **38**: 1321–1328.

Reybrouck G. 1986. Handwashing and hand disinfection. *J Hosp Infect* **8**: 5–23.

Romaguera C, Vilaplana J. 2000. Occupational contact dermatitis from ylang-ylang oil. *Contact Derm* **43**: 251–257.

Samaila D, Toy B, Wang R, Elegbede A. 2004. Monoterpenes enhanced the sensitivity of head and neck cancer cells to radiation treatment *in vitro*. *Anticancer Res* **24**: 3089–3095.

Santoyo S, Cavero S, Jaime L, Ibanez E, Senorans J, Reglero G. 2006. Supercritical carbon dioxide extraction of compounds

with antimicrobial activity from *Origanum vulgare* L.: determination of optimal extraction parameters. *J Food Prot* **69**: 369–375.

Scardamaglia L, Nixon R, Fewings J. 2003. Compound tincture of benzoin: a common contact allergen? *Australas J Dermatol* **44**: 180–184.

Schmidt E, Jirovetz L, Buchbauer G *et al.* 2005. Antimicrobial testing and gas chromatographic analysis of aroma chemicals. *J Essential Oil Bearing Plants* **8**: 99–106.

Schnitzler P, Schon K, Reichling J. 2001. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture. *Pharmazie* **56**: 343–347.

Schnuch A, Lessmann H, Geier J, Frosch P, Uter W. 2004. Contact allergy to fragrances: frequencies of sensitization from 1996 to 2002. Results of the IVDK. *Contact Derm* **50**: 65–76.

Schuhmacher A, Reichling J, Schnitzler P. 2003. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 *in vitro*. *Phytomedicine* **10**: 504–510.

Seymour R. 2003. Additional properties and uses of essential oils. *J Clin Periodontol* **30**(S5): 19–21.

Shkurupii V, Kazarinova N, Ogirenko A, Nikonov S, Tkachev A, Tkachenko K. 2002. Efficiency of the use of peppermint (*Mentha piperita* L) essential oil inhalations in the combined multi-drug therapy for pulmonary tuberculosis. *Probl Tuberk* **4**: 36–39.

Sinico C, De Logub A, Laia F *et al.* 2005. Liposomal incorporation of *Artemisia arborescens* L. essential oil and *in vitro* antiviral activity. *Eur J Pharm Biopharm* **59**: 161–168.

Sirinivas SR. 1986. *Atlas of Essential Oil*. EA Weiss: Bronx, NY, USA

Skocibusic M, Bezic N, Dunkic V, Radonic A. 2004. Antibacterial activity of *Achillea clavennae* essential oil against respiratory tract pathogens. *Fitoterapia* **75**: 733–736.

Snow L, Hovanec L, Brandt J. 2004. A controlled trial of aromatherapy for agitation in nursing home patients with dementia. *J Altern Complement Med* **10**: 431–437.

Sokmen A, Gulluce M, Akpulat A *et al.* 2004. The *in vitro* antimicrobial and antioxidant activities of the essential oils and methanol extracts of endemic *Thymus spathulifolius*. *Food Control* **15**: 627–634.

Srivastava K. 1986. Onion exerts antiaggregatory effects by altering arachidonic acid metabolism in platelets. *Prostaglandins Leukot Med* **24**: 3–50.

Srivastava K, Tyagi O. 1993. Effects of garlic-derived principle (ajoene) on aggregation and arachidonic acid metabolism in human blood platelets. *Prostaglandins Leukot Essential Fatty Acids* **49**: 587–595.

Steinberg D. 1997. Low density lipoprotein oxidation and its pathobiological significance. *J Biol Chem* **272**: 20963–20966.

Stratton S, Dorr R, Alberts D. 2000. The state-of-the-art in chemoprevention of skin cancer. *Eur J Cancer* **36**: 1292–1297.

Takahashi Y, Inaba N, Kuwahara S, Kuki W. 2003. Antioxidative effect of Citrus essential oil components on human low-density lipoprotein *in vitro*. *Biosci Biotechnol Biochem* **67**: 195–197.

Talpur N, Echard B, Ingram C, Bagchi D, Preuss H. 2005. Effects of a novel formulation of essential oils on glucose-insulin metabolism in diabetic and hypertensive rats: a pilot study. *Diabetes Obes Metab* **7**: 193–199.

Tan P, Zhong W, Cai W. 2000. Clinical study on treatment of 40 cases of malignant brain tumor by elemene emulsion injection. *Zhongguo Zhong Xi Yi Jie He Za Zhi* (*Chin J Integ Trad Western Med*) **20**: 645–648. Abstract is in English and available on www.pubmed.org.

Teissedre P, Waterhouse A. 2000. Inhibition of oxidation of human low-density lipoproteins by phenolic substances in different essential oils varieties. *J Agric Food Chem* **48**: 3801–3805.

Tepe B, Donmez E, Unlub M *et al.* 2004. Antimicrobial and antioxidative activities of the essential oils and methanol extracts of *Salvia cryptantha* (Montbret et Aucher ex Benth.) and *Salvia multicaulis* (Vahl). *Food Chem* **84**: 519–525.

Tepe B, Sokmen M, Akpulat A, Daferera D, Polissiou M, Sokmen A. 2005. Antioxidative activity of the essential oils of *Thymus sipyleus* subsp. *sipyleus* var. *sipyleus* and *Thymus sipyleus* subsp. *sipyleus* var. *rosulans*. *J Food Eng* **66**: 447–454.

Thomas N, Panchagnula R. 2003. Combination strategies to enhance transdermal permeation of zidovudine (AZT). *Pharmazie* **58**: 895–898.

Thomson M, Ali M. 2003. Garlic: A review of its potential use as an anti-cancer agent. *Curr Cancer Drug Targets* **3**: 67–81.

Tomaino A, Cimino F, Zimbalatti V *et al.* 2005. Influence of heating on antioxidant activity and the chemical composition of some spice essential oils. *Food Chem* **89**: 549–554.

Ultee A, Bennik M, Moezelaar R. 2002. The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen *Bacillus cereus*. *Appl Environ Microbiol* **68**: 1561–1568.

Ultee A, Kets W, Smid E. 1999. Mechanisms of action of carvacrol on the food-borne pathogen *Bacillus cereus*. *Appl Environ Microbiol* **65**: 4606–4610.

Vaddi H, Ho P, Chan Y, Chan S. 2002. Terpenes in ethanol: haloperidol permeation and partition through human skin and stratum corneum changes. *J Control Rel* **81**: 121–133.

Valenzuela A, Sanhueza J, Alonso P, Corbari A, Nieto S. 2004. Inhibitory action of conventional food-grade natural antioxidants and of natural antioxidants of new development on the thermal-induced oxidation of cholesterol. *Int J Food Sci Nutr* **55**: 155–162.

Van De Graaff E, Steinhubl S. 2001. Complications of oral antiplatelet medications. *Curr Cardiol Rep* **3**: 371–379.

Veien N, Rosner K, Skovgaard G. 2004. Is tea tree oil an important contact allergen? *Contact Derm* **50**: 378–379.

Vilaplana J, Romaguera C. 2002. Contact dermatitis from the essential oil of tangerine in fragrance. *Contact Derm* **46**: 108–113.

Villar R, Maria A, Ramon F. 1997. Inhibition by ajoene of protein tyrosine phosphatase activity in human platelets. *Biochim Biophys Acta* **1337**: 233–240.

Vinitketkumnuen U, Lertprasertsuk N. 1997. Inductive and suppressive effects of crude lemongrass on phase II xenobiotic-metabolizing enzymes. *Mutat Res/Fund Mol Mech Mutagen* **379**(1) (Suppl): S179.

Wagstaff A, Faulds D, Gona K. 1994. Acyclovir: a reappraisal of its antiviral activity. Pharmocokinetic properties and therapeutic efficacy. *Drugs* **47**: 153–205.

Wannissorn B, Jarikasem S, Siriwangchai T, Thubthimthed S. 2005. Antibacterial properties of essential oils from Thai medicinal plants. *Fitoterapia* **76**: 233–236.

Wattenberg L. 1992. Inhibition of carcinogenesis by minor dietary constituents. *Cancer Res* **52**: 2085s–2091s.

Wendakoon C, Sakaguchi M. 1995. Inhibition of amino acid decarboxylase activity of *Enterobacter aerogenes* by active components in spices. *J Food Prot* **58**: 280–283.

Williams A, Barry B. 1989. Essential oils as novel human skin penetration enhancers. *Int J Pharm* **57**: R7–R9.

Williams A, Barry B. 1991. Terpenes and the lipid-protein-partitioning theory of skin penetration enhancement. *Pharm Res* **8**: 17–24.

Williams A, Barry B. 2004. Penetration enhancers. *Adv Drug Delivery Rev* **56**: 603–618.

Wu C, Chung J, Tsai S, Yang J, Sheen L. 2004. Differential effects of allyl sulfides from garlic essential oil on cell cycle regulation in human liver tumor cells. *Food Chem Toxicol* **42**: 1937–1947.

Wu C, Sheen L, Chen H, Kuo W, Tsai S, Li C. 2002. Differential effects of garlic essential oil and its three major organosulfur components on the hepatic detoxification system in rats. *J Agric Food Chem* **50**: 379–383.

Yamada K, Mimaki Y, Sashida Y. 2005. Effects of inhaling the vapor of *Lavandula burnatii* super-derived essential oil and linalool on plasma adrenocorticotropic hormone (ACTH), catecholamine and gonadotropin levels in experimental menopausal female rats. *Biol Pharm Bull* **28**: 378–379.

Yamada K, Miura T, Mimaki Y, Sashida Y. 1996. Effects of inhalation of chamomile oil vapours on plasma ACTH level in ovariectomized rat under restriction stress. *Biol Pharm Bull* **19**: 1244–1246.

Yasni S, Imaizumi K, Sin K, Sugano M, Nonaka G. 1994. Identification of an active principle in essential oils and hexane-soluble fractions of *Curcuma xanthorrhiza* Roxb. showing triglyceride-lowering action in rats. *Food Chem Toxicol* **32**: 273–278.

Yazdanparast R Alavi M. 2001. Antihyperlipidaemic and antihyper-cholesterolaemic effects of *Anethum graveolens* leaves after the removal of furocoumarins. *Cytobios* **105**: 185–191.

Yengopal V. 2004a. The use of essential oil mouthwashes as preprocedural rinses for infection control. *SADJ* **59**: 247–248, 250.

Yengopal V. 2004b. Essential oils: some lesser known uses and properties for improved oral health. *SADJ* **59**: 381–382, 384.

Yengopal V. 2004c. Essential oils and interdental hygiene. *SADJ* **59**: 155, 157, 170.

Yengopal V. 2004d. Preventative dentistry: essential oils and oral malodour. *SADJ* **59**: 204, 206.

Yuri T, Danbara N, Tsujita-Kyutoku M *et al.* 2004. Perillyl alcohol inhibits human breast cancer cell growth *in vitro* and *in vivo*. *Breast Cancer Res Treat* **84**: 251–260.

Zarkovic N. 2003. 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. *Mol Aspects Med* **24**: 281–291.

Zheng G, Kenny P, Lam L. 1992. Inhibition of benzo[a]-pyrene-induced tumorigenesis by myristicin, a volatile aroma constituent of parsley leaf oil. *Carcinogenesis* **13**: 1921–1923.